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Empirical support for the efficacy of CBT in treating depression suggests that the 
majority of clients will respond to this intervention. However, the more nuanced, and 
clinically relevant, question of"Which clients will respond to CBT for depression?" has 
been difficult to answer. Research efforts have focused on two different approaches to 
this question. One approach focuses on trajectories of symptom change within the first 
weeks of treatment to identify clients who are most likely to achieve response. A second 
approach looks to pretreatment client variables such as hopelessness and dysfunctional 
attitudes to identify clients who are more likely to respond. The cun·ent study is the first 
to simultaneously compare these two approaches to the prediction of treatment outcome. 
The sample consists of 222 clients ( 65.32% female, 92.79% Caucasian), ages 18 through 
64 (M = 27.85, SD 11.28), receiving treatment for mood and anxiety disorders (59% 
v 
met criteria for comorbid disorders) in a CBT oriented psychology training clinic. Results 
suggest that the rate of change in depressive symptoms over the first five treatment 
sessions significantly and consistently predicted outcome over and above the majority of 
pretreatment variables, except for precontemplation stages of change scores and initial 
severity of depression and anxiety symptoms. Similarly, rate of change in anxiety 
symptoms significantly predicted outcome on two of the three measures over and above 
the majority of pretreatment variables, except for hopelessness and initial severity of 
anxiety symptoms. Post hoc analyses revealed different predictors of outcome when 
trajectories of change and pretreatment variables were examined separately. Both rates of 
change and a number of pretreatment variables predicted outcome. Finally, pretreatment 
predictors of rate of early symptom change such as a contemplative orientation to change 
and therapist experience, were identified which may suggest that therapists should target 
these factors to potentially maximize rapid early symptom change, and in turn outcome. 
The findings are discussed in terms of their implications regarding methodological 
approaches to treatment outcome research and treatment planning for adults with 
comorbidities. 
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CHAPTER I 
INTRODUCTION 
Rates of Response to Cognitive Behavioral Therapy 
1 
Over 325 Cognitive Behavioral Therapy (CBT) outcome studies reveal large 
effects for treating adult depression, panic disorder, generali zed anxiety disorder, social 
phobia, and posttraumatic stress disorder (Butler, Chapman, Fo n an, & Beck, 2006). 
Meta-analyses have demonstrated that CBT is more effective than wait-lists, untreated 
controls, ph armacotherapy, behavior therapy, and a heterogeneous group of other 
therapies in treating over 1 6  different disorders (e.g., Dobson, 1 989; Westen & Morrison, 
2001 ). The adaptation of CBT protocols targeting a wide range of presenting problems 
has made CBT the most commonly cited empirically supported treatment (EST) included 
in the Best Practice Guidelines produced by the American Psychological Association 
(Chambless, Baker, Baucom, et al., 1998). 
Although the above s ummary compellingly identifies CBT as an effective 
treatment for a number of disorders, a closer look at the literature suggests response rates 
are actually quite variable. For instance, rates of response to CBT in randomi zed clinical 
trials (RCTs) range from as low as 40% for moderate to severe depression (DeRubeis, 
Hollon, Amsterdam et al. ,  2005) to as high as 90% for panic disorder (Clark, Salkovskis, 
Hackmann, Middleton, Anastasiades, & Gelder, 1 994). Inconsistent rates of response for 
2 
CBT targeting the same disorder have been observed even when the same treatment 
protocol is used. For example, two studies using the same protocol for group treatment 
of social phobia (Heimberg, 1 991)  reported response rates of 7 5% and 3 6% (Heimberg et 
al, 1 990 and Hope et al, 1995 respectively) even though no obvious differences between 
the studies, in terms of sample characteristics, therapist experience, or outcome measure, 
were observed. 
These very different response rates to the same treatment protocol suggest that 
although CBT has been identified as an EST, it is not effective for all clients and as such 
it may not be that informative to estimate a single overall response rate to CBT. This is 
certainly not a new idea. Four decades ago, Gordon Paul articulated the question, "What 
treatment, by whom, is most effective for this individual with that specific problem, under 
which set of circumstances?" (Paul, 1 967, p. 1 1 1  ). This question has guided 
psychotherapy research in the hunt for predictors, moderators, and mediators of response, 
but it has not yet yielded especially constructive or consistent results. 
Predictors of Response 
For instance, numerous predictors of response to treatment for anxiety and 
depression have been identified. These predictors can be categorized into three broad 
domains: clinical, cognitive and contextuaL Initial levels of symptom severity (Haby, 
Donnelly, Corry, & Vos, 2006; Merrill, Tolbert, & Wade, 2003) and therapist level of 
training (DeRubeis et al., 2005; Driscoll, Cukrowicz, Reitzel, Hernandez, Petty, & Joiner, 
2003 ; Grey, Salkovskis, Quigley, Clark, & Ehlers, 2008; Lutz, Leon, Martinovich, Lyons, 
& Stiles, 2007; Stein & Lambert, 1 995; Weertman & Arntz, 2007) have been identified 
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as predictors in clients with both depression and anxiety disorders. Nonspecific predictors 
of response for treatment of depression include dysfunctional attitudes, age, marital 
status, hopelessness (Barber & DeRubeis, 1 99 2), severity of depression (Hamilton & 
Dobson, 200 2), and readiness to change (Lewis, Simons, Silva, et al., 2009; Lichtenberg 
& Hummel, 2000). Fewer predictors have emerged from the anxiety literature; however, 
initial severity, comorbid depression, and motivation to change have been identified as 
predictors of response (e.g., Chambless, Tran, & Glass, 1997; Keijsers, Hoogduin, & 
Schaap, 1994). 
Predictors of response are indeed useful to clinicians particularly in selecting 
treatment and treatment components . However, similar to the response rates reviewed 
above, predictors of response are more variable than would be desired. That is, 
dysfunctional at ti tudes, for example, have been identified as a predictor of response in 
some, but not all, depression treatment outcome studies leaving clinicians to decide to 
what extent pretreatment levels of dysfunctional at titudes should guide their treatment 
planning. 
It may be that a different approach to answering Gordon Paul's question would be 
more illuminating. One such avenue for research involves taking a closer look at the 
rates, patterns and processes of change in symptoms over the co urse of psychotherapeutic 
treatment. That is, rather than restricting outcome analyses to pre-post group mean 
comparisons whereby the focus is on the relationship bet ween pretreatment factors and 
posttreatment symptom scores, analysis of within treatment outcome data (session -by­
session) may be more revealing. This level of analysis might provide the perspective 
necessary to unpack the inconsistent and variable findings repor ted above. Said 
differently, althou gh successful response to treatment would remain the primary target 
and focus of psychotherapy outcome research effor ts, perhaps a better understanding of 
the different pathways to response would aid in e ffor ts to identify factors predictive of 
outcome with greater consistency. 
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Indeed this line of research appears to be a fruitful endeavor. For instance, Ilardi 
and Craighead ( 1 994) observed a rapid response to psychotherapy such that 60 -80% of 
depressive symptom improvement occurred within the first four weeks of treatment. 
Numerous other studies found similar patte rns of rapid early response upon reanalysis of 
the data (e.g., Beckham, 1989 ; Blackbu rn & Bishop, 1983; Fennell & Teasdale, 1 987; 
Rush et al .,  1 977). These rapid rates of depressive symptom reduction observed during 
psychotherapeutic treatment have been found to predict outcome at follow-up more so 
than s imilar patte rns observed in nonpsychological therapies (Gilboa-Schechtman & 
Shahar, 2006) . Although rapid response to treatment was originally obser ved in 
depressed clients, this patte rn has since been observed in clients treated for panic disorder 
(e.g., Penava, Otto, Maki, & Pollack, 1 998), alcohol abuse (e.g., Breslin, Sobell, Sobell, 
Buchan, & Cuningham, 1 997) and in mixed samples of clients (Crits-Christoph, 
Connolly, Gallop, et al. ,  200 1) predicting success at follow-up. The predictive validity of 
rap id early rates of response in psychotherapy appears to be a robust finding in the 
literature. That is, rapid response has been consistently identified as a powerful predictor 
of successful outcomes, more so than any of the nonspecific pretreatment variables 
identified in the literature. 
However, the rapid response and pretreatment predictor findings reported above 
were derived from analyses at the level of the group 's mean . Implicit in Gordon Paul's 
question is the notion that individuals differ in impor tant ways. Thus it is possible that 
analysis at the level of the individual might identify even more meaningful pat terns and 
processes of change. That is, focus on group means without consideration of individual 
heterogeneity may obscure other patterns that could be identified at the individual level 
that might similarly be associated (or even more strongly associated) with good 
outcomes. 
Sudden Gains Phenomenon 
Tang and DeRubeis ( 1999) attempted to unpack the observed rapid early rates of 
response by taking the analysis down to the level of the individual in an investigation of 
patterns of response to treatment for Major Depressive Disorder (MDD). Their research 
was also motivated by the desire to identify mechanisms of change in CBT. Cognitive 
mediation was an obvious candidate given the theory upon which the therapy is based 
(Beck, Rush, Shaw, & Emery, 1 979). Therapeutic alliance quickly became an opposing 
candidate, championed by those who suppor t the notion of nonspecific mechanisms of 
change (B urns & Nolen-Hoeksema, 199 2).  In Tang and DeRubeis' ( 1999) reanalysis of 
session by session data from the Treatment for Depression Collaborative Research 
Program (TDC RP; Elkin et al., 1 989), they observed a phenomenon whereby clients 
demonstrated sudden, dramatic, enduring decreases in depressive symptoms from one 
session to the next. They dubbed this phenomenon "sudden gains". Sudden gains were 
observed in approximately 50% ofthe clients, accounted for over 50% of the client 's 
5 
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total symptom reduction, typically occurred early in treatment (median = session 5), and 
were related to recovery (79% of clients who experienced sudden gains recovered). Tang 
and DeRubeis ( 1999) interpreted this data as support for the cognitive mediation 
hypothesis in that significantly greater cognitive change was observed in the session prior 
to the sudden gain. And, they observed significant increases in the therapeutic alliance in 
the session after the gain was made suggesting that symptom reduction led to reported 
increases in therapeutic alliance. These findings ignited a flurry of research efforts to 
investigate this phenomenon in different samples. 
Since Tang and DeRubeis ' ( 1 999) original work, the number of studies examining 
sudden gains is well into the double digits (e.g., Gaynor et al. , 2003 ; Hardy et al., 2005; 
Stiles et al. , 2003; Tang et al. ,  200 2). Importantly, sudden gains have been observed in a 
variety of set tings: RCTs (e.g., Tang, DeRubeis, Beberman, & Pham, 2005; Vittengl, 
Clark, & Ja rrett, 2005), "real world" settings (e.g., Stiles, Leach, Barkham, et al., 2003), 
and training clinics (e.g., Greenfield, 2009). The replication across sites and set tings 
suggests that sudden gains is a reliable phenomenon that could inform our understanding 
of patte rns of response. 
Similar to the findings regarding rapid early rates of change, the sudden gains 
phenomenon was first identified in the depression literature and has since expanded to 
include a variety of other clinical disorders. Sudden gains have been observed in panic 
disorder (Clerkin, Teachman , & Smith-Janik, 2008), generalized anxiety disorder 
(Present, Crits-Christoph, Gibbons, et al ., 2007), social phobia (Ho finann, Schulz, 
Meuret, Moscovitch, & Suvak, 2006), bulimia nervosa (Grilo, Masheb, & Wilson, 2006), 
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alcohol abuse (Breslin, Sobell, Sobell, Buchan, & Cunningham, 1997), and in clients with 
comorbidities (Tschitsaz & Lutz, 2009). In addition, although the motivation for studying 
sudden gains developed in an effort to examine the cognitive mediation hypothesis in 
CBT --thus thinking sudden gains would be specific to CBT --researchers have observed 
sudden gains in Interpersonal Psychotherapy (Kelly, Cyrano wski, & Frank, 2007), 
Supportive -Expressive Psychotherapy (Tang, Luborsky, & Andrusyna, 200 2), 
Nondirective Supportive Therapy (Gaynor, Weersing, Kolko, Brimaher, Heo, & Brent, 
2003), Psychoeducational group therapy (Kelly, Roberts, & Ciesla, 2005), 
Pharmacotherapy, and in Pill Placebo (Vittengl, Clark, & Jarrett, 2005). Sudden gains do 
not appear to be specific to any one treatment (e.g., CBT, IPT), or any one kind of 
treatment (e.g., psychotherapy, pharmacotherapy), nor do sudden gains appear to be 
specific to treatment but perhaps common to improvement however achieved. That is, 
Kelly, Roberts, and Bottonari ( 2007) observed 60% of depressed college students 
experienced sudden gains outside of the treatment context suggesting sudden gains may 
be a natural part of the course of depression and possibly other disorders given the 
diverse range of disorders in which sudden gains have been observed. 
Despite numerous attempts, the literature has yet to identify who experiences 
·sudden gains. Sudden gains do not appear to be related to age, ethnicity, marital status, 
employment status, gender, or socioeconomic status (Gaynor et al. ,  2003 ; Kelly et al. ,  
2007). In addition, none of  the following factors appear to  be  related to sudden gains: 
dysfunctional attitudes, attributional style, hopelessness, level of cognitive distor tions, 
stress, or overall functioning (Gaynor et al., 2003; Hardy et al., 2005; Kelly et al., 2005;  
Kelly et al ., 2007) . Without identifying predictors of sudden gains it remains difficult to 
anticipate which clients might go on to experience this privileged pathway to response . 
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Unfor tunately, the lack of specificity is not the only limitation of the sudden gains 
literature. Researchers repeatedly acknowledge the somewhat arbitrary criteria on which 
the phenomenon is based (Tang & DeRubeis, 1 999). Specifically, Tang and DeRubeis 
originally described this phenomenon in an explora tory investigation of the session-by­
session data. They created the three-par t criteria in an effor t to characterize the seemingly 
meaningful pattern to facilitate replication. Although some effort has been made to 
maintain the original criteria, it is not uncommon for researchers to omit one of the three 
criteria (e .g., Gaynor, Weersing, Kolko, Bi rmaher, Heo, & Brent, 2003) or alter one or 
more of the criteria (e.g., Hardy et al., 2005; Kelly, Rober ts,  & Bottonari, 2007; Stiles, 
Leach, Bar kham, et al., 2003 ; Vittengl, Clark, & Jarrett, 2005) thus limiting the ability to 
generalize findings across studies. 
Recently, some researchers have reached consensus regarding the criteria for 
sudden gains but even so, the characteristics of the sudden gains differ dramatically from 
one sample to the next. For instance, the median session for a sudden gain to occ ur ranges 
from session 4 (Vittengl et al. ,  2005) to session 1 1  (Busch et a l., 2006); the percent of 
total improvement captured by the gain ranges from 5 1  (Tang & DeRubeis, 1999) to 105 
(i.e., the gain was greater than the symptom reduction maintained by te rmination; Stiles, 
et al., 2003); and, the percent of sudden gains reversed ranges from 17  (Tang & 
DeRubeis, 1 999) to 57 (Gaynor et al., 2003). In addition to the abovementioned 
limitations, the sudden gains phenomenon represents only one of numerous possible 
pathways to acute phase response that is experienced by as few as 1 7% of clients in 
routine clinical care (Stiles et al., 2003). 
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Taken together, the sudden gains literature may be less informative than originally 
perceived. That is, sudden gains were thought to be the product of a mechanism of 
change specific to CBT for depression, but instead it seems to lack specificity al together. 
Rather than providing empirical suppor t for the underpinnings of cognitive theory of 
depression, researchers seem to have identified a pattern of discontinuity common to 
symptom change in a small subset of individuals with mental illness. 
Expanding on Sudden Gains 
This is not to say that the sudden gains phenomenon is a worthless research 
pursuit, but rather it seems impor tant to meaningfully characteri ze more ofthe sample 
beyond the subgroup who experience sudden gains. More recently researchers have 
expanded their investigation of the sudden gains phenomenon. For instance, Busch, 
Kanter, Landes, and Kohlenberg ( 2006) extended their analysis to include pretreatment 
and first-session gains in a small community sample (N 38) receiving Cognitive 
Therapy for Major Depressive Disorder (MDD). They found that 100% of clients who 
experienced a first -session gain recovered -a significantly greater number of clients 
recovered as compared to those with only a pretreatment gain ( 67% recovery rate) and 
those with neither a pretreatment gain nor a first -session gain ( 46% recovery rate). 
Whereas typically this work has identified "successful" pathways to response, Tschitsa z 
and Lut z ( 2007) found that clients who experienced both sudden gains and losses fared 
markedly poorer than those who experienced either gains or losses --an effect si ze less 
than .4 on the BDI as compared to large e ffect si zes (e.g., .8) for those who experienced 
sudden gains. Together, these findings build the case for considering gains and losses 
made by clients that cannot be captured by the sudden gains criteria alone. 
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The next logical step for this line of research might be to examine, in one study, 
the abovementioned gains and losses so as to possibly characteri ze the di fferent aspects 
of the seemingly discontinuous trajectory of each client in the sample. Specifically, this 
would include examination of pretreatment gains, first session gains, sudden gains, 
sudden losses and those who experience both sudden gains and losses. Because previous 
research has observed a single client to experience one or more of these kinds of 
gains /losses, the unique predictive utility of these individual characteri zations remains 
unclear because countless possible profile combinations of these gains/losses exist. 
Growth Curve Modeling 
As an alternative approach, Haas, Hill, Lambert, and Morrell ( 200 2) used 
hierarchical linear modeling (HLM) to examine the relationship between rate of early 
symptom change and outcome. Indeed, consistent with earlier reports using group mean 
data, Haas and colleagues found that rapid rates of early response over the first 3 therapy 
sessions, modeled to include individual variability, predicted outcome. One advantage of 
this approach to analyses is that it utili zes the session-by-session, individual data (like the 
sudden gains literature), and it provides an informative picture of the sample 's trajectory 
that is more comprehensive than the sudden gains literature affords .  
Growth C urve Modeling ( GCM), as employed in the work of Haas and 
colleagues, has a number of additional advantages over the sudden gains approach but 
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also over pre -post group mean analysis and the perhaps most typical repeated measures 
Analysis of Variance (ANOVA). Not only do ANOVA approaches require that the data 
adhere to difficult to meet assumptions (e.g., fully balanced data, equally spaced intervals 
between sessions) which GCM does not require, but also ANOVA approaches cannot 
accommodate both time-invariant and time-varying covariates, or continuous predictors 
of response as GCM allows (Laurenceau, Hayes, & Feldman, 2007). Perhaps an even 
greater advantage of GCM is that both inter-individual and intra-individual change can be 
modeled simultaneously (Collins & Sayer, 2000; Rogosa & Willet t, 1985). That is, 
whereas ANOV A approaches treat the above-mentioned individual di fferences in change 
trajectory as measurement error, GCM considers these observations as meaningful 
heterogeneity in change pathways. 
In GCM, trajectories of change can thus be characteri zed by replicable models 
that when compared across samples might bring the field closer to identifying a typical 
trajectory of response while considering individual variability. Laurenceau, Hayes, and 
Feldman ( 2007) repo rted that understanding the shape and rate of change through GCM 
is an important initial step if we are to improve psychotherapy outcomes. Specifically, 
they implied that understanding the di fference in pat terns of symptom change between 
responders and non-responders might provide insight into ways to improve rates of non­
response. Indeed, Speer and Greenbaum ( 1 995) compared five methods for computing 
significant individual client change in psychotherapy and found GCM to be the most 
sensitive, recommending it be used for treatment outcome research whenever possible. 
Perhaps surprisingly, despite the advantages and appropriateness of employing GCM 
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over more traditional approaches, until recently few studies have examined change in 
symptom severity over the course of treatment using GCM. By bridging the previously 
described approaches to outcome research we might be able to resolve the silent debate in 
the literature regarding which matters most in predicting therapy outcome: trajectories of 
early change or pretreatment variables. 
Two studies, to our knowledge, have done exactly that; they have simultaneously 
examined the role of trajectories of change and pretreatment variables in an effort to 
determine predictors of relapse at follow-up. Santor and Segal (2002) compared initial 
depressive severity, rates of early change (weeks 1 -3), rates of change in the first 1 0  
weeks, and rates o f  change in the first 2 0  weeks. They found rates of change in the first 
1 0  weeks predicted symptom return at 3-months over and above initial severity and rates 
of early or later change. More recently, Gilboa-Schechtman and Shahar (2006) found, in 
their comparative analysis, that rapid rates of change in the first 4 weeks of therapy 
predicted outcome at 1 2- and 1 8-months over and above initial severity and remoralizer 
status. Given the broad range in weeks since therapy commenced (weeks 4 1 0) in which 
rapid response significantly predicted outcomes at follow-up, it will be important for 
future research to identify, with some degree of consistency, by which session rapid 
change should be expected. In addition, these studies were somewhat limited in that they 
included only initial symptom severity as a candidate pretreatment predictor of response. 
Future studies examining a wider range of previously identified predictors of response 
would make an important contribution to the literature. 
1 3  
For instance, as the push to disseminate CBT into the community rises, concerns 
have been raised about the role of comorbidity. Specifically, although some studies have 
identified comorbidity as a predictor of outcome (e.g., Gelhart & King, 200 1 ;  Laberge, 
Gauthier, Cote, & Plamondon; Reich, Warshaw, Peterson, & White, 1 995), others have 
not (e.g., Joormann, Kosfelder, & Schulte, 2005 ; McLean, Woody, Taylor, & Koch, 
1 998; Persons, Roberts, & Zalecki, 2003). As comorbidity is now referred to as "the rule 
rather than the exception" studies examining the extent to which comorbidity predicts 
rates of early change and outcomes are particularly important. Another understudied 
approach would be to simultaneously compare the rates of change in both depressive and 
anxiety symptoms. No studies, to our knowledge, have simultaneously modeled both 
symptom sets in the context of trying to understand the differential impact of rates of 
early symptom change on ultimate therapy outcomes. 
The Present Study 
In sum, predictors of outcome are thought to guide the clinician in treatment 
decision making to promote successful response. Unfortunately, the literature identifying 
pretreatment variables as predictors of distal outcomes has yielded inconsistent results 
making it difficult for practicing clinicians to inform their work in accord with the 
existing literature. On the other hand, the robust nature of rapid rates of early response as 
a predictor of outcome has guided the UK's approach to their widely disseminated 
psychotherapeutic treatment protocol: therapy sessions are delivered twice weekly for the 
first six weeks in an effort to maximize the potential for a "rapid response". Roz Shafran, 
"Chair of CBT" in the UK's national effort to "Improve Access to Psychological 
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Therapies", urged clinical psychologists at the most recent Association of Behavioral and 
Cognitive Therapies Convention ( 2009) to "experiment" with upping session dosage 
early in treatment in an effort to bring about this rapid response given its observed effect 
on outcome. 
However, prior to disseminating an altered approach to session dose, it seems 
important to answer the following question in the same study: Which matters most in 
terms of successful response: rate of early symptom change or pretreatment factors? 
Therefore, the present study sought to move beyond the traditional pre -post group mean 
method of analysis approach to investigating predictors when examining outcome data 
from a Psychology training clinic. Instead, a bridging of methodologies was employed to 
advance the empirical work regarding patterns of symptom change in psychotherapy 
outcome studies. Specifically, a robust finding in the literature is that rapid early rates of 
response are predictive of outcome; however, the sudden gain phenomenon characteri zes 
only one possible privileged pathway to recovery leaving much of the sample 
uncharacteri zed. Conversely, Latent Growth Curve Modeling (LGCM) fits a model to the 
sample as a whole that accommodates individual variability in both initial status and 
growth rate by first generating individual growth curves. Such modeling of symptoms 
from the early sessions of therapy allowed several hypotheses to be tested including the 
extent to which baseline factors predicted individual variability in symptom trajectories 
and whether and to what extent these early rates of change predicted treatment outcome. 
And, in an attempt to the merge these lines of inquiry, both rates of early symptom 
change and previously identified pretreatment variables predictive of response were 
examined to determine which matters more in terms of achieving good outcomes. 
Specific Aims 
The aims of this study were five-fold. 
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Aim 1: To examine trajectories of depressive symptomatology during the first five 
treatment sessions and the extent to which pretreatment factors relate to these depressive 
trajectories. 
Aim 2: To compare how well depressive symptom trajectories versus pretreatment 
variables predict ultimate therapy outcome. 
A im 3: To examine trajectories of anxiety symptomatology during the first five treatment 
sessions and the extent to which pretreatment factors relate to the anxiety trajectories. 
Aim 4: To compare how well anxiety symptom trajectories versus pretreatment variables 
predict ultimate therapy outcome. 
Aim 5: This study was also designed to test two hypotheses regarding the relationship 
between depressive and anxiety symptoms and their change over the course of CBT. 
Specifically, the fol lowing two hypotheses were tested: 1) depressive and anxiety 
symptoms are more distally related through latent constructs; (2) depressive and anxiety 
symptoms are more proximally related as evidenced by significant time-varying covariate 
relationships between symptom scores within each session. 
Participants 
CHAPTER II 
METHOD 
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Participants were adults (ages 18-64) who voluntarily presented for therapy in a 
Psychology training clinic at the University o f  Oregon from the fall of 2005 to the spring 
of2009. Of the 269 clients who sought treatment at the clinic (i.e. , completed a phone 
screen), 236 went on to complete an intake. O fthose who completed an intake, 1 4  clients 
were re ferred for services elsewhere leaving data from 222 clients in the current sample. 
Both completers (i.e., clients who reached a "natural" termination from therapy) and 
those who prematurely terminated were included in analyses. 
Procedures 
Client Assessment Procedure and Inclusion Criteria. The initial stage o f  the 
assessment included a standardized phone screen , administered by our clinic coordinator , 
to obtain the following in formation: age , refe rral source, medication usage , suicidality , 
counseling history, and presenting problems. Because our clinic does not o ffer 24 -hour 
crisis support, clients with acute problems (e.g. , those who endorsed suicidality and 
articulated a plan) were connected with a di fferent community agency e quipped with 
crisis-ready resources. Acute suicidality, extreme psychosis and severe drug or alcohol 
dependence were essentially the only exclusion criteria for enrollment in therapy. 
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Clients who were deemed an appropriate fit with our clinic were assigned to a 
therapist who set up the initial intake appointment. The Semi-Structured Clinical 
Interview for the Diagnostics and Statistics Manual, Fourth Edition (SCID-1, First, 
Spitzer, Gibbon, & Williams, 1997) was administered at intake. The interview took 45 to 
1 20 minutes (depending on the complexity of the clinical presentation) and yielded 
information necessary for making Axis I diagnoses. Clients who demonstrated symptoms 
consistent with our "exclusion" criteria during the intake were similarly referred out for 
more appropriate services. All other clients were offered services in the Psychology 
Training Clinic; these clients constitute the current study sample regardless of the length 
of time in treatment. 
Measures 
The Beck Depression Inventory (BDI-I; Beck, Ward, Medelsohn, Mock, & 
Erlbaugh, 1 96 1 ;  Beck et al, 1979) is a 21-item self-report measure that assesses severity 
of somatic, affective, cognitive, vegetative, and behavioral symptoms associated with 
depression. Each item is scored on a 0 (no symptoms) to 3 (very severe symptoms) scale. 
Psychometric properties of the BDI have been well documented (Beck, Steer & Garb in, 
1 988). Cronbach alphas from the present study demonstrated strong internal reliability 
over time (range in a: .91 - .94).  The total score (ranging from 0 to 63) served as one of 
two primary symptom and outcome measures for this study as it was obtained each 
session the client met with the therapist. Higher total scores indicate greater depressive 
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symptom severity. Intake and the first five treatment session scores were included in the 
growth modeling. The following cutoffs were employed for interpretation of total scores 
(Beck et al ., 1961): 0-9 =not depressed, 10-18 =mild-moderate depression, 19-29 
moderate-severe depression, 30-63 =severe depression. 
The Beck Anxiety Inventory (BAI; Beck & Steer, 1993) is a 21-item self-report 
measure assessing severity of anxiety symptoms. Each item is scored on a 0 (no 
symptoms) to 3 (very severe symptoms) scale. The psychometric properties of the BAI 
have been well supported by the literature (Beck, Epstein, Brown, Steer, 1988). Cronbach 
alphas from the present study demonstrated strong internal reliability over time (range in 
a: .90 - .93). The total score (0 to 63) served as the other primary outcome for the study 
as it was obtained each session the client met with the therapist. Higher scores indicate 
greater anxiety symptom severity. Intake and the first five treatment session scores were 
included in the modeling. The abovementioned BDI cutoffs for assigning a descriptive 
label were used with the BAI scores as well. 
The Stages of Change Schedule (SOCS; McConnaughy, Prochaska, & Velicer, 
1983) is a 32-item self-report measure. Eight items correspond to each of the four 
subscales that represent the transtheoretical model thought to measure readiness to 
change: Precontemplation, Contemplation, Action, and Maintenance. A Likert scale from 
0 (strongly disagree) to 5 (strongly agree) is used to respond to each item. The SOCS has 
demonstrated adequate internal consistency with adults (coefficient alphas: . 7 5 to . 87; 
McConnaughy, Prochaska, & Velicer, 1983). Multiple scoring procedures for the stages 
of change questionnaire (DiClemente, Schlundt, & Gemmell, 2004) are available in the 
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literature. McConnaughy et al. ,  (1989) employed cluster analysis to produce client/patient 
profiles whereas DiClemente and colleagues (2004) calculated a "readiness score" as an 
alternative way to approximate stage status. Though scoring procedures such as cluster 
analysis and DiClemente's "readiness score" may utilize the information gleaned from 
the SOCQ in a manner consistent with the theoretical framework for the stages of change, 
these methods are limited in terms of: (l) interpretability, (2) ability for cross study 
comparisons, and (3) clinical utility. To address these limitations, the current study 
employed a third alternative approach to scale scoring (Dozois, Westra, Collins, Fung, & 
Garry, 2004; Lewis, Simons, Silva et al. , 2009; Rogers, Martin, Anthongy, Massaro, 
Danley, Crean, & Penk, 2001) whereby four separate readiness to change scores were 
derived through simple summing subscale items. 
The Dysfunctional Attitudes Scale (DAS; Weissman & Beck, 1978) is a 40-item 
self report scale that measures patterns of maladaptive thinking or "depressogenic 
schema" thought to constitute a cognitive diathesis to depression. A Likert scale from 1 
(totally disagree) to 7 (totally agree) is used to respond to each item. The scale includes 
two subscales: Achievement and Interpersonal; however, the psychometrics of the DAS 
suggest the measure is best used as a whole (coefficient alpha: .90; Oliver, & Baumgart, 
1985). Higher scores indicate more dysfunctional attitudes. Total and subscale scores at 
intake were included in predictor analyses. 
The Beck Hopelessness Scale (BHS; Beck, Weissman, Lester, & Trexler, 1974) is 
a 20-item T/F self report measure of pessimism; higher scores indicate greater 
hopelessness. The psychometric properties suggest high internal consistency (coefficient 
alpha: .93). The scale has demonstrated sensitivity to changes in depression over time. 
Total scores at intake were included in predictor analyses. 
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The Global Assessment of Functioning (GAF; Spitzer R. L. , Gibbon M. , Williams 
J. B. W., & Endicott J. 1 996) is a scale used by therapists to rate the social, occupational , 
and psychological functioning of the client from I to 1 00. Higher scores indicate greater 
functioning. Psychometric properties suggest moderate reliability of the GAF (coefficient 
alpha: .74; Hilsenroth , Ackerman , & Blagys , 2000). Intake GAF scores were included in 
predictor analyses. 
Comorbidity. Clients were assigned to one of three comorbidity groups based on 
the number of diagnoses assigned from the SCID-I: ( 1 )  No Diagnosis; (2) Single 
Disorder; (3) Comorbid Disorders. That is , clients who did not meet criteria for an Axis I 
diagnosis (i.e. , they demonstrated sub-threshold symptoms) were included in the "No 
Diagnosis" group. Clients who met criteria for a single disorder (e.g. , Major Depressive 
Disorder , Social Phobia, Posttraumatic Stress Disorder) were included in the "Single 
Disorder" group. Finally , clients who met criteria for more than one DSM-IV disorder 
(e.g., Major Depressive Disorder and Social Phobia) were included in the "Comorbid 
Disorders" group. Comorbidity groupings were considered a potential covariate in 
subse quent analyses. 
Medication Status. During the initial phone screen, clients were asked whether 
they were currently taking psychotropic medication to treat their condition. Client 
responses were coded either "yes" or "no". Medication status was considered a potential 
covariate in subse quent analyses. 
2 1  
Responders versus Non-responders. The criteria put forth by Jacobson, Roberts, 
Berns, and McGlinchey ( 1 999) for clinically significant change as per the reliable change 
index were used to classify responders versus non-responders. As such, clients who 
experienced at least a 50% reduction in BDI scores or who moved to a BDI score o fless 
than or e qual to 10 were considered responders. Because the BAI is based upon the same 
scale, the same criteria were applied to determine responders versus non-responders. I f  
clients recovered on one measure (e.g., BDI) but not the other (e.g., BAI) they were 
considered partial responders. This variable was coded to allow for inclusion in analyses 
as a continuous measure o f  outcome: 0 = Non-responder, 1 = Partial Responder, 2 = 
Responder. 
Treatment 
Therapy and Training. Therapists who participated in the practicum were trained 
to deliver CBT and to in form their therapy using a cognitive case conceptualization. 
Training consisted o f  weekly didactics and role play in addition to either individual or 
group supervision. Typically in their first year o f  practicum therapists received individual 
supervision beginning with one depression only case (or one anxiety only case) using a 
standard CBT protocol. Therapists' supervisors increased therapist caseloads based upon 
therapist readiness and skillfulness reaching a maximum o f  four individual cases within 
the first year. Therapists choosing to complete a second, third, fourth, etc. year o f  
practicum could have been assigned to individual or group supervision and could have 
received additional training in CBT variants such as Acceptance and Commitment 
Therapy (ACT). Neither therapist competency nor fidelity to treatment was measured. 
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Therapeutic delivery was expected to be more flexible in terms o f  focus and also in terms 
of number o f  sessions as compared to RCTs following a manualized protocol. 
Therapists 
All therapists were clinical psychology doctoral students at the University o f  
Oregon enrolled in the CBT practicum. Thirty-three therapists in their 2nd through 6th 
year o f  the doctoral program delivered CBT to an ongoing case load of 4 clients. 
Therapists were predominantly female (90.04%) and the average number of months o f  
CBT training at the initial session with the client was 1 4.63 (SD 10 .69). Un fortunately, 
therapists' previous and additional experiences data were not collected. Therapist level of 
training was measured in months since the therapist entered practicum and was included 
as a covariate in all subse quent analyses. 
Data Analytic Plan 
The five primary aims of the study were addressed through separate analytic 
steps .  As stated, the first aim was to examine trajectories o f  depressive symptomatology 
during the first five treatment sessions and the extent to which pretreatment factors relate 
to these depressive trajectories. A second aim was to compare how well depressive 
symptom trajectories versus pretreatment variables predict ultimate therapy outcome. 
Aims 3 and 4 were identical to aims 1 and 2 with the exception that anxiety symptoms 
were the focus o f  investigation. Finally, a fifth aim o f  this study was to test two 
hypotheses regarding the relationship between depressive and anxiety symptoms and 
their change over the course of CBT. 
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Analytic Step 1 re quired baseline analyses to (a) broadly characterize the sample, 
(b) confirm/disconfirm suspect covariates (i.e., therapist level of training, comorbidity 
and medication status), (c) determine the extent to which collinearity existed among 
prospective predictors, and (d) assess the degree to which the symptom scores reflected 
multivariate normality. Analytic Step 2 involved Latent Growth Curve Modeling 
(LGCM) to identify the best fit model characterizing the early trajectory of client 
depressive and anxiety symptoms. Analytic Step 3 examined predictors of trajectories of 
early change in an attempt to explain any heterogeneity observed in initial status and 
growth rate of depressive and anxiety symptom severity. Analytic Step 4 included the 
combination of latent growth factors representing trajectories of early change and 
pretreatment factors to determine which factors "mattered most" in predicting outcome. 
Finally, Analytic Step 5 involved simultaneous modeling of depressive and anxiety 
symptom change through (a) parallel and (b) time-varying covariate models. 
Statistical Analyses 
Baseline analyses were run using SAS Version 9. 1 (SAS Institute, Cary, NC). 
Specifically, general linear models (GLM) were used to compare the comorbidity groups 
(i.e., No Diagnosis, Single Disorder, and Comorbid Disorders) on depressive and anxiety 
symptom severity at baseline and across the first five treatment sessions, and a posteriori 
Student t-tests were conducted if an omnibus test was significant at the .05 level. Non­
directional statistical tests were employed. Student t-tests were conducted to compare 
depressive and anxiety symptom severity across medication status. Bivariate Pearson 
product-moment correlations were run to examine the relation between baseline clinical, 
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cognitive, and contextual variables. Cohen's (1988) interpretation of correlation size was 
adopted: .5  = "large", .3 = "moderate", .1 = "small". 
LGCM was run using MPlus 5.1 (Muthen & Muthen, 2007). The full information 
maximum likelihood algorithm was invoked to handle missing data in all analyses and 
expectation maximization served as the algorithm for maximization. This approach 
estimates missing data using all observed information available (e.g., outcomes, 
co variates) in the model. Client attrition, referral out, and variability in therapist behavior 
limited the completeness of the depressive and anxiety symptom assessments. Complete 
BDI and BAI data across all time points was available on 139 (62.2%) and 141 (63.5%) 
clients, respectively. The mean- and variance-adjusted Chi-square and degrees of 
freedom (x2, Bollen, 1989), as well as the Comparative Fit Index (CFI, Bentler, 1990) and 
Root Mean Squared Error of Approximation (RMSEA, Steiger, 1990), were used to 
assess goodness of model fit. Specifically, non-significant Chi-square values, and values 
greater than .95 for CFI and less than .06 for RMSEA (Hu & Bentler, 1999) served as 
benchmarks for adequate fitness. All regression models were run in MPlus and included 
in the overall growth curve modeling framework. Therefore, model fitness could be 
reassessed and compared to the best fitting baseline model using the Chi-square 
difference test. 
Analytic Step 1. 1 :  Baseline Analyses 
CHAPTER III 
RESULTS 
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Baseline Demographics. Clients (N 222) receiving therapy in our training clinic 
were students (68.02%) and community members (3 1 .98%). Clients were predominantly 
Caucasian (92.79%) ranging in age from 1 8  to 64 years (M= 27.85, SD = 1 1 .28). Two­
thirds ofthe sample were female (65 .32%). Nearly 10% of clients did not meet criteria 
for an Axis I disorder (n 2 1),  34.23% met criteria for a single diagnosis (n 76), and 
53 .60% met criteria for comorbid diagnoses (n = 1 19) .  Twenty-two percent of clients 
endorsed suicidality and 40.28% reported taking medication at intake. Overall, mild­
moderate depressive and anxiety symptom severity characterized symptomatology at 
intake. Global Assessment of Functioning scores suggested the sample was experiencing 
moderate impairment. Average levels of hopelessness were minimal: the mean score (M 
7.33, SD = 4.92) was below the clinical cutoff of 9. The highest subscale score of the 
Stages of Change Scale indicates the best description of the sample's readiness to change 
at intake. As such, baseline scores indicated the sample, on average, could be 
characterized as contemplative, suggesting that clients were aware of a distressing life 
situation, but were not yet ready to fully take action toward change. See Table 1 for a 
complete list and breakdown ofbaseline demographics. 
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Preliminary Analyses with Suspect Covariates. GLMs assessing group differences 
in depressive and anxiety symptom severity for each of the first five treatment sessions 
were run to determine whether comorbidity status (i.e., No Diagnosis, Single Diagnosis, 
Comorbid Diagnosis) should be included as a covariate in subsequent analyses. The 
omnibus GLM confirmed that both the BDI and BAI differed between comorbidity 
groups. A posteriori Student t-tests revealed that clients with comorbid disorders 
demonstrated higher BDI scores each session from intake to session four with a trend (p 
= .069) in the same direction at session five (see Table 2). The same pattern was mirrored 
by the relationship between comorbidity status and BAI scores with the exception that 
clients with comorbid diagnoses continued to demonstrate significantly higher BAI 
scores at session five. These preliminary analyses confirmed the need to control for 
comorbidity status in all subsequent analyses. 
It was decided, a priori, to include therapist level of training as a covariate, given 
the nature ofthe training clinic. That is, perceived client complexity, severity, and/or 
chronicity were intentionally matched to therapist level of training. Surprisingly, baseline 
analyses did not reveal substantive evidence that therapist level of training was indeed 
related to baseline markers of severity or complexity. Rather, therapist level of training 
was only moderately correlated with baseline anxiety symptom severity, but not 
depressive symptom severity or comorbidity groupings (see Table 3). Despite this, the 
decision to include therapist level of training as a covariate in all growth models was 
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Table 2 
Means and Standard Deviations of Depressive and Anxiety Symptom Severity Across 
Comorbidity Groupings 
Session # No Diagnoses Single Comorbid 
Diagnoses Diagnoses 
IDT 13 .48 (9.29)a 14.02 (8 .27)a 1 9.41 (8.68)b 
S lDT 8 .50 (5 .87)a 1 0.03 (7.49)a 14.23 (8.6 1 )b 
S2DT 7.38 (4.21 )a 9.3 1 (6 .68)a 1 3 .48 (8.83)b 
S3DT 8.57 (5 .69)a 7.79 (5.87)a 12 .38 (7.83)b 
S4DT 5 . 1 5  (4.83)a 8 .49 (6.47)a 12.75 (7.82)b 
S5DT 6.67 (4.89) 8 .50 (6.61 )  10.86 (7.92) 
IAT 13 .86 ( 10.43)a 14.44 (8.99)a 20.54 ( 1 1 .63)b 
S lAT 1 1 .25 (8.74)a 1 0.23 (7.39)a 1 7. 10  ( 10.24)b 
S2AT 1 1 .37  (7.98)a 10.38 (7.95)a 1 5 .41  (9.39)b 
S3AT 9.40 (8 .23)a 9.04 (7.37)a 14.35 (9.45)b 
S4AT 9. 1 5  (9.35)a 8.99 (7.08)a 1 5 .79 ( 1 1 . 1 7)b 
S5AT 8 .58  (7.94)a 9.3 1 (7.47)a 1 3 .8 1  (10.06)b 
Note. I =  Intake. DT = Depression Total. AT = Anxiety Total. Means in the same row 
that do not share subscripts are significantly different at p < .05. 
Table 3 
Bivariate Correlations: Therapist Level ofTraining, Symptom Severity, Comorbidity 
T train BAI BDI CG 
T train 1 .00 0.22** 0. 1 1  0.089 
BAI 1 .00 0.40*** 0.26*** 
BDI 1 .00 0.28*** 
CG 1 .00 
Note. T_train = Therapist Level of Training. BDI = Beck Depression Inventory. BDI = 
Beck Anxiety Inventory. CG = Comorbidity Grouping. 
retained because of the likelihood that therapist level of training was related to a 
28 
clinically relevant variable, such as chronicity, not captured by our dataset but potentially 
important in terms of client response. 
29 
The final covariate under consideration--medication status (yes/no) at intake--
was, however, significantly related to baseline depressive and anxiety symptom severity: 
reported use of psychotropic medication was related to elevated baseline symptom 
severity. These significant differences were observed throughout the first five treatment 
sessions (Table 4). Therefore, medication status was included as a covariate in all 
subsequent models. 
Table 4 
Depressive and Anxiety Symptom Severity across Medication Status 
Medication Status 
Variables Yes (n = 87) No (n = 129) 
IDT 1 9 .78 (8.09)a 14.97 (7.34)b 
SlDT 1 3 .82 (7.93)a 1 1 .28 (8. 1 8)b 
S2DT 12.44 (7.98) 10.50 (7.91)  
S3DT 1 1 . 10 (7. 5 1 )  9.74 (6.7 1 )  
S4DT 1 1 .28 (7.03) 9.95 (7.5 1) 
S5DT 1 0.67 (7.68) 9. 10  (7.24) 
IAT 20.44 ( 12.54)a 1 5 .94 (9.78)b 
S l AT 16.64 ( 1 1 .23)a 12.90 (8 .80)b 
S2AT 14.66 ( 10 . 16) 12. 1 5  (8 .29) 
S3AT 1 3 .47 (9.78) 1 1 .02 (8.54 
S4AT 1 5 .09 ( 1 1 .60)a 1 1 .47 (9.47)b 
S5AT 1 3 .99 ( 1 0.48) 10.73 (8.78) 
Note. I =  Intake. DT = Depression Total. AT = Anxiety Total. 
Correlational Analyses. Baseline depressive symptom severity was moderately 
correlated with anxiety symptom severity and hopelessness. Small, but significant 
positive correlations were observed between depressive symptom severity and the 
following pretreatment variables: contemplation stages of change, DAS, the DAS 
achievement subscale, and age. Both depressive and anxiety symptom severity were 
30 
moderately negatively co rrelated with global functioning. Large significant correlations 
were observed between the DAS subscales. Moderate positive correlations were observed 
between the following SOCS subscales: contemplation, action , and maintenance. See 
Table 5 for a complete listing of bivariate correlations between baseline variables. 
Mean Levels of Depressive and Anxiety Symptoms over the First Five Treatment 
Sessions. Sample means from the first five treatment sessions were plotted to examine 
trajectories and used to guide subse quent modeling of both BDI and BAl. Figure I 
suggested that both sets of symptom scores (BDI and BAI) followed a roughly linear 
trajectory indicating that a strict linear slope would indeed serve as an appropriate 
baseline model for comparison (see Table 6 for means and SDs). Each of the first six BDI 
and BAI total scores (from intake through session 5) were examined to see if multivariate 
normality as assumed by maximum likelihood estimations was met. Although slight 
skewness was observed on each of the symptom scores , this deviation from normality 
was not sufficient to warrant a transformation that would have rendered results less 
interpretable (Table 7). BDI and BAI over the first five treatment sessions were all 
moderately to highly co rrelated (Table 8). 
Analytic Step 2. 1: Aim 1 
Trajectories of Early Change. Latent growth curve modeling (LGCM) was 
employed in order to characterize the trajectories of client response to treatment over the 
first five treatment sessions. Specifically, a series of a priori specified growth models 
were examined to identify the best-fitting and most parsimonious model characterizing 
individual differences in initial status and change in depressive and anxiety symptoms 
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Figure 1 
BDI and BAI Trajectories during the First Five Treatment Sessions 
2 0  
1 8  
1 6  
14 
1 2  j _ _ 1 0  -+- BDI 
8 -1--·-- - -- ----·-·-·- -- ·--·-·-------- ---- -- -- - BAI 
6 
4 +----
2 
0 ---,---,----,---,----, 
Intake 51 52 53 54 55 
over the first five treatment sessions. The first step specified unconditional two growth 
factor models. That is, the only parameters included in the modeling were the mean and 
variance of both the intercept and slope that were allowed to randomly vary within the 
person (Muthen & Muthen, 1 999), no restrictions were imposed, and a test of the 
assumption that BDI scores followed a strict linear trajectory was conducted. If fit was 
less than adequate, then linear spline models were estimated and finally, a quadratic 
growth factor included. Spline models constrain at least two time points in the model and 
allow the remaining time points to freely vary (Meredith & Tisak, 1 990); this method 
accommodates nonlinearity that may be demonstrated by individuals in the sample. In the 
current application, intercept loadings were fixed to one and the first two loadings for the 
slope factor were constrained to zero and one, respectively, with the remaining loadings 
free to be estimated. Linear spline models allow for flexibility in the linear trajectory by 
3 3  
modeling piecewise curves or crooked lines in which the straight line segments do not 
necessarily map onto the overall straight line while testing the assumption that a linear 
trend is the most accurate characterization of the BDI scores. Linear spline models 
confound both shape (i.e., nonlinear) and slope (i.e., trend upward or downward) within 
the growth rate factor estimate given the flexibility described above (see Stoolmiller, 
1995 for more technical details). The intercept and slope for each growth model were 
regressed on the following co variates in all modeling estimates: therapist level of training 
(months since entry to practicum), medication status (yes/no), and comorbidity status (No 
Diagnosis, Single Diagnosis, Comorbid Diagnosis). 
Table 6 
BDI and BAI Descriptive Statistics 
Measure Time N Mean {SD} Minimum Maximum 
BDI Intake 220 16.96 8.99 0 45 .5  
Session 1 178 12.36 8.33 0 45 .0 
Session 2 172 11.41 8.08 0 49.0 
Session 3 165 10.44 7.34 0 35 . 5  
Session 4 151 10.63 7 .58 0 37.0 
Session 5 144 9.74 7 .41 0 35 .0 
BAI Intake 219 17.78 11.07 0 59.0 
Session 1 177 14.40 9.81 0 62.0 
Session 2 171 13 .24 9.06 0 48.0 
Session 3 162 12.08 9.02 0 48.0 
Session 4 149 12.98 10.35  0 52.0 
Session 5 142 11.97 9.39 0 50.0 
Note. BDI =Beck Depression Inventory. BAI Beck Anxiety Inventory. 
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Table 7 
Skewness and Kurtosis Statistics: BDI and BAI 
BDI BAI 
Session # Skewness Kurtosis Skewness Kurtosis 
Intake 0.43 -0.10 0.85 0.53 
Session 1 0.98 1.69 1.15 2.57 
Session 2 1.06 2 .23 1.05 1.00 
Session 3 0.93 0.77 1.13 1.31 
Session 4 0.74 0.16 1.24 1.58 
Session 5 0.91 0.54 1.34 1.98 
Note. BDI =Beck Depression Inventory. BAI =Beck Anxiety Inventory. 
The strict linear and quadratic models were rejected as they fit the data poorly as 
evidenced by significant Chi Square values, CFI lower than .95, and RMSEA greater than 
.06. However, the linear spline model in which the residual covariances of the BDI scores 
were constrained to be equal was chosen as these additional constraints made the model 
most parsimonious with fit statistics in the desired range: x2 (23) = 28.522, p .19; CFI = 
0.994; RMSEA .033.  Figure 2 provides a graphical representation of the final, best-fit 
linear spline growth curve model. The R-square statistics depicted in the figure indicate 
the proportion of variance in the BDI scores accounted for by the growth factors is 
relatively high suggesting that the linear spline slope/shape does well in reproducing the 
observed growth curves. 
The model suggests that, on average, the depressive symptom trajectories began 
at a moderate severity and fairly rapidly decreased over the first five treatment sessions 
(see Table 9 for coefficient estimates). Significant variability was observed in both initial 
status and growth rate. The non-significant result of the test of zero covariance between 
the intercept and slope suggests that the client's initial status of depressive symptom 
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severity has no influence on the rate or direction of change in depressive symptom 
severity over the next five sessions of treatment. Concomitant psychotropic use and 
comorbidity were positively associated with baseline levels of depressive symptom 
severity whereas level of therapist level o f  training was not , when controlling for all 
covariates. Only baseline medication status predicted rate of change in BDI symptoms 
early in therapy: concomitant psychotropic use was related to an accelerated decrease in 
depressive symptomatology over the first five treatment sessions (see Table 10 for 
regression coefficients) .  The R-square statistic for the latent curve parameters suggests 
that the covariates significantly accounted for variation in the intercept (R2 = 0. 1 94, p 
.001)  but not the slope (R2 = 0. 1 1 9, p . 1 39). 
Analytic Step 3. 1 
Pretreatment Predictors ofTrajectories of Early Change. We examined whether 
and to what extent pretreatment variables explained the significant heterogeneity in the 
initial status (intercept) and growth rate (slope) of depressive symptomatology over the 
first five treatment sessions. Based on previously identified predictors of psychotherapy 
outcome for depression and anxiety , 16 pretreatment variables from three categories were 
explored: ( 1 )  Clinical variables: comorbidity , depression symptom severity , anxiety 
symptom severity, and global functioning; (2) Cognitive variables: hopelessness, 
readiness to change (i.e., four subscales: precontemplation , contemplation, action, 
maintenance), and dysfunctional attitudes (overall DAS and its two subscales: 
achievement and interpersonal); and, (3) Contextual variables: age , gender , student status, 
and medication status. First , each time-invariant variable was examined in a univariate 
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Figure 2 
Graphical Representation of Best-Fit BDI Model 
20.67<: f;\ 1 8 .96*<:
f;\
 
1 1 .56<: f;\
 1 0. 14*<:
f;\
 1 3 .84
�
f;\
 1 6.30
�
�
 
v 2.886 v 2 .886 v 2.886 v 2.886 v 2.886 v � r'\ � r'\ � r'\ � r'\ �  r'\ � 
IDT S l DT S2DT S3DT S4DT SSDT 
Note. e = residual variance. IDT = Intake BDI total score. S lDT = Session 1 Depression 
Total Score and so on. I =  Intercept. S = Slope. T_Train = Therapist Level of Training. 
Med = Medication Status. CoGrp = Comorbidity Grouping. * p < .05. 
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Table 9 
Parameter Estimates for BDI Growth Models with Covariates 
Mean of Variance Mean of Parameter Covariance: 
level of level change Variance of level and 
change change 
Model Coeff. Coeff. Coeff. Coeff. (SE) Coeff. (SE) 
{SE) {SE) {SE) 
Linear spline with 8.99***  50.09*** -3 .22**  8.62* -8.29 
time score residual ( 1 .56) (8. 1 6) (0.95) (4.07) (4.99)+ 
covariances fixed to 
e ual 
Note. BDI Beck Depression Inventory. Coeff. == Coefficient. SE = Standard Error. df= 
degrees of freedom. ***  p < .0001 .  * *  p < .00 1 ,  * p < .05, + p < . 1 .  
Table 10 
Covariate Regression Coef icients in Best-Fitting BDI Model 
Covariate 
Therapist Level of Training 
Medication Status 
Comorbidity Status 
Therapist Level of Training 
Medication Status 
Comorbidity Status 
Note. SE Standard Error 
Latent Factor Coefficient {SE) 
Intercept 0.050 (0.056) 
4.44 ( 1 . 1 7) 
3 .71  {0.85) 
Slope -0.0002 (-.034) 
-2. 1 3  (0.69) 
-0.32 {0.5 1) 
p-value 
.37 
<.0001 
<.0001 
.96 
.002 
.53 
growth model. Second, a multivariate analysis including all pretreatment variables was 
run to examine the extent to which each variable explained variability above and beyond 
other predictors included in the model. The best-fit linear spline with the inclusion of 
each regression equation continued to fit the data well as evidenced by fit statistics in the 
desired range and no significant deterioration in fit as per the Chi-square fitness test. 
The univariate analyses (including the three co variates: therapist level of training, 
medication status, comorbidity status) identified the following variables as predictors of 
BDI initial status :  comorbidity status, medication status, anxiety symptom severity, 
student status, global functioning, hopelessness, dysfunctional attitudes, and 
achievement-oriented dysfunctional attitudes (see Table 1 1) .  Specifically, comorbidity 
(as opposed to having no or a single diagnosis), concomitant psychotropic usage, and 
community member (as opposed to student) status were all related to greater depressive 
symptom severity at intake. Similarly, hopelessness, higher dysfunctional attitudes, and 
specifically, achievement-oriented dysfunctional attitudes were related to greater 
depressive symptom severity at intake. 
39 
Only three pretreatment factors were related to growth rate in these univariate 
predictor analyses. First, concomitant psychotropic usage predicted a steeper decline in 
depressive symptomatology over the first five sessions of treatment. Second, higher 
initial levels of a contemplative orientation to change predicted an accelerated decline in 
depression symptomatology. Third, having more initial interpersonally-oriented 
dysfunctional attitudes predicted a steeper decline in growth rate ofBDI scores. 
Next, a multivariate predictor analysis that included all pretreatment factors was 
run (see Table 1 2). This model identified the following as significant predictors of initial 
status: concomitant psychotropic usage, anxiety symptom severity, community member 
status, hopelessness, and global functioning. Comorbidity and dysfunctional attitudes 
dropped out of the multivariate model as predictors ofBDI initial status. Concomitant 
psychotropic usage, student status, and a contemplative orientation to change were 
identified as significant predictors of an accelerated decline in depressive 
symptomatology in the multivariate analyses. 
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In sum, a number of predictors of initial status of depressive symptom severity 
were identified. When all other pretreatment variables were accounted for, medication 
status, anxiety symptom severity, student status, global functioning, and hopelessness 
were significantly related to initial depressive symptom severity. Medication status, 
student status, and a contemplative orientation to change were found to predict rate of 
change in BDl. The predictors summarized here were included in the following outcome 
analyses. 
Analytic Step 4. 1 :  Aim 2 
Predictors of Outcome: Trajectories ofChange vs Pretreatment Factors. 
Trajectories of early change in depressive symptom severity were further investigated to 
determine the extent to which initial status and rate of growth predicted outcome in terms 
of responder status and level of depressive symptom severity at termination. Previously 
identified predictors of response (e.g., comorbidity, therapist level of training, readiness 
to change, and dysfunctional attitudes) were also included in the growth modeling 
framework. Specifically, outcome was regressed on these potential predictor variables 
concurrently with the latent growth factors to determine which factors "mattered most" in 
terms of predicting heterogeneity in outcome. 
Prior to conducting outcome analyses in the context of growth models, 
rudimentary pre-post group mean analyses were run. Indeed, change in both depressive 
and anxiety symptom severity was significant from baseline to termination reflective of 
large effect sizes (see Table 1 3  and 14) .  In addition, nearly half the sample was classified 
as a "Responder" with an additional 28.38% classified as a "Partial Responder" leaving 
45 
less than a quarter in the "Non-responder" class (see Table 1 5) .  Almost two-thirds of the 
sample (65.77%) were considered to have responded as per the BDI whereas 60.8 1 %  
responded as per BAI scores. The average number of sessions across completers and non-
completers of treatment was 12.04 (SD = 10.84) whereas when only completers of 
treatment were considered (n = 149) the average number of sessions was 1 5 .88 (SD = 
1 0.74) as compared to 4.01 (SD = 5 .38) for non-completers. 
Table 1 3  
Change in BD!from Pre- to Post-Treatment 
Group Intake BDI t-value df p-value Effect 
BDI Sizes 
M (SD} M{SD} 
Total Sample 1 6.95 (8.99) 8.60 (8.07) 14.08 1 8 1  <.0001 0.98 
No Diagnosis 1 3 .48 (9.29) 5.25 (5 .28) 3 .56 1 5  .0028 1 .09 
Single Diagnosis 14.02 (8.27) 7 .61  (6.75) 7 .60 60 <.0001 0.85 
Comorbid Diagnoses 1 9.41 {8.682 9.69 {8.93) 1 1 .36 1 04 <.0001 1 . 10 
Note. BDI Beck Depression Inventory. 
Table 1 4  
Change in BAI from Pre- to Post-Treatment 
Group Intake BAI Termination t-value df p-value Effect 
BAI Sizes 
M(SD} M(SD} 
Total Sample 17.78 ( 1 1 .07) 9.53 (8. 87) 1 1 .5 1 1 82 <.0001 0 .82 
No Diagnosis 13 .86 ( 10.43) 7.06 (9.04) 2.30 1 6  .035 0.70 
Single Diagnosis 14 .44 (8 .99) 8 .5 1 (8.68) 6.50 60 <.0001 0.67 
Comorbid Diagnoses 20.54 {1 1 .63} I 0.54 {8.90} 9.5 1 104 <.0001 0.96 
Note. BAI = Beck Anxiety Inventory. 
Table 1 5  
Responders, Partial Responders, Non-responders 
Group Responders 
on BDI 
Responders 
on BAI 
Responder 
Overall 
Partial Non-
Responders Responders 
Total Sample 146 (65 .77) 135  (60.8 1 )  109 (49. 1 0) 63 (28.38) 
No Diagnosis 14  (66.67) 1 5  (7 1 .43) 12 (57. 14) 5 (23. 8 1 )  
Single Disorder 52 (66.67) 48 (6 1 .54) 37 (47.44) 26 (33.33) 
Comorbid Disorders 80 (65.04) 72 (58.54) 60 (48.78) 32 (26.02) 
Note. BDI = Beck Depression Inventory. BAI = Beck Anxiety Inventory 
50 (22.52) 
4 ( 19.05) 
15 ( 19.23) 
3 1  (25.20) 
Three outcome variables were then regressed on the intercept and slope of the 
best-fitting baseline growth model to identifY the extent to which heterogeneity in the 
latent growth parameters predicted distal outcomes: ( 1 )  overall responder status (Non-
responder, Partial Responder, versus Responder); (2) Non-responder versus Responder 
46 
on the BDI; and, (3) BDI total score at termination. Given the aforementioned variability 
in length of treatment, number of sessions was controlled for in all subsequent outcome 
analyses. These analyses would thus answer the question, "Does initial status of symptom 
severity or rate of change across the first five treatment sessions predict outcome?" In 
addition, the inclusion of previously identified predictors of response regressed on the 
same distal outcomes would answer the questions, "Do pretreatment variables predict 
outcome over and above latent growth factors? Which factors matter most?" 
The first BDI outcome model regressed anxiety symptom severity, student status, 
hopelessness, and global functioning on the intercept and student status and 
contemplation scores on the slope, as per the results of the multivariate predictor 
analyses. The model also controlled for number of sessions in addition to the three 
47 
co variates. In order to examine the incremental utility of trajectories of early change and 
pretreatment variables, all factors were included simultaneously as predictors of the 
overall trichotomous responder variable. Specifically, responder status was regressed on 
the intercept and slope in addition to pretreatment variables identified in the literature as 
predictors of response (i.e., age, gender, student status, global functioning, hopelessness, 
precontemplation, contemplation, action, and maintenance stages of change, 
dysfunctional attitudes, achievement-oriented DAS, interpersonally-oriented DAS, 
anxiety symptom severity, comorbidity, medication status, and therapist level of training) 
in the growth modeling framework. 
This model fit the data relatively well, ·l ( 106) 123.56, p = . 12 ;  CFI = 0.983 ; 
RMSEA .027. Slope predicted to responder status such that an accelerated growth rate 
predicted higher responder status (e.g., Responder) whereas the intercept was not 
identified as a significant predictor (see Table 1 6) .  Not a single pretreatment variable 
predicted response over and above latent growth factors. 
The second BDI outcome model was identical to the one examined above except 
that the dichotomous responder variable as per change in BDI scores at termination 
served as the outcome measure. In addition to regressing the responder status on the 
intercept and slope, the same pretreatment variables listed above were tested in the 
growth modeling framework. 
The model still adequately fit the data well (x\106) = 1 20.02,p = . 1 7, CFI = .987, 
RMSEA = . 024). Slope predicted to responder status such that an accelerated growth rate 
predicted higher responder status (e.g., Responder) whereas the intercept was not 
Ta
bl
e 
16
 
P
re
di
ct
or
s 
of
 D
is
ta
l O
ut
co
m
es
 
M
od
el
 
O
ut
co
m
e 
In
te
rc
ep
t 
p-
Sl
op
e 
p-
Pr
e 
p-
A
nx
ie
ty
 
p-
R 
V
ar
ia
bl
e 
C
oe
ff
 
va
lu
e 
C
oe
ff
 
va
lu
e 
va
lu
e 
Se
ve
ri
ty
 
va
lu
e 
(S
E
) 
SE
) 
B
D
I 
R
es
po
nd
er
 
-0
.0
08
 
.6
16
 
-0
.2
54
 
.0
22
 
43
.7
 
St
at
us
 
(0
.0
15
) 
(0
.1
11
) 
B
D
I 
-0
.0
08
 
.3
64
 
-0
.1
65
 
.0
14
 
0.
16
6 
.0
46
 
52
.3
 
R
es
po
nd
er
 
(0
.0
09
) 
(0
.0
67
) 
(0
.0
83
) 
St
at
us
 
B
D
I T
ot
al
 
0.
80
0 
<0
.0
01
 
0.
48
5 
<0
.0
01
 
-0
.1
42
 
.0
04
 
56
.5
 
Sc
or
e 
{0
.1
05
} 
{0
.1
10
) 
(0
.0
49
) 
N
ot
e. 
C
oe
ff
=
 C
oe
ffi
ci
en
t. 
SE
 =
St
an
da
rd
 E
rr
or
. B
D
I =
B
ec
k 
D
ep
re
ss
io
n 
In
ve
nt
or
y.
 P
re
= 
Pr
ec
on
te
m
pl
at
io
n 
SO
C
S 
su
bs
ca
le
 s
co
re
s. 
49 
identified as a significant predictor. The precontemplation stage of change subscale was 
the only pretreatment variable to predict response when the latent growth factors were 
included in the model: higher pretreatment precontemplation scores predicted higher 
responder status (e.g., Responder). 
The third and final BDI outcome model included the BDI total scores at 
termination as the outcome measure. In addition to regressing the termination scores on 
the intercept and slope, the same pretreatment variables listed above were tested in the 
growth modeling framework with the exception of student status. 
This model fit the data well (x2( 1 06) = 1 30.68, p = .052, CFI = .978, RMSEA = 
.032). Both slope and intercept predicted to responder status such that an accelerated 
growth rate and greater intake depressive symptom severity predicted lower BDI scores 
at termination. Greater intake anxiety symptom severity predicted to lower BDI scores at 
termination. No other pretreatment variables predicted response when the growth factors 
were simultaneously considered. 
In sum, the slope (i.e., rate of early change) of the linear spline growth curve 
modeling the BDI scores at intake and over the first five treatment sessions predicted 
outcome on all three outcome measures, whereas the intercept only predicted total BDI 
scores at termination. These latent growth factors demonstrated predictive validity even 
when controlling for therapist level of training, comorbidity, and medication status as 
well as number of sessions and a number of other pretreatment variables. 
Precontemplation subscale scores and anxiety symptom severity were the only 
other pretreatment variables to predict response when included in the growth curve 
50 
modeling framework; neither of the identified pretreatment factors consistently predicted 
response across all the outcome measures. These results suggest that rate of early change 
in depressive symptom severity predicts outcome over and above pretreatment factors. 
Analytic Step 2.2: Aim 3 
Aims 3 and 4 essentially repeated the analytic steps followed above. Aim 3 was to 
examine trajectories of anxiety symptomatology during the first five treatment sessions 
and the extent to which pretreatment factors relate to the anxiety trajectories. Aim 4 was 
to compare how well anxiety symptom trajectories versus pretreatment variables predict 
ultimate therapy outcome. 
Trajectories of Early Change. Similar to the BDI growth modeling, the strict 
linear and quadratic models were rejected as they fit the data poorly as evidenced by 
significant Chi Square values, CFI lower than .95, and RMSEA greater than .06. 
However, the linear spline model in which the BAI score residual covariances were 
constrained to be equal was chosen as these additional constraints made the model most 
parsimonious with fit statistics in the desired range: x2 (23) = 27.79, p = .22; CFI = 0.994; 
RMSEA = .03 1 .  Figure 3 provides a graphical representation of the final, best-fit model 
for BAI scores. The R-square statistics depicted in the figure indicate the proportion of 
variance in the time scores accounted for by the growth factors is relatively high 
suggesting that the linear spline model did well in reproducing the observed growth 
curves. 
Figure 3 
Graphical Representation of Best-Fit BAI Model 
4 l .i5<:::fc\ 46. 1 4<:::fc\ 2J.IO<:::fc\ 1 5 .23*<::fc\ 3l.74<::fc\ 27.73<::fc\ 
\..::_) 5.525* \..::_) 5.525* \..::_) 5.525* \..::_) 5.525* \..::_) 5.525* \..::_) 
� 1'\ � 1'\ � 1'\ � 1'\ �  
1'\ �  
IAT S l AT S2AT S3AT S4AT S5AT 
Note. e = residual variance. IAT = Intake BAI total score. S lAT Session 1 Anxiety 
Total Score and so on. I =  Intercept. S = Slope. T_Train = Therapist Level of Training. 
Med = Medication Status. CoGrp == Comorbidity Grouping. * p < .05. 
5 1  
The model suggests that, on average, the anxiety symptom trajectories began at a 
moderate severity and decreased over the first five treatment sessions, though not at as 
rapid a rate as the BDI scores declined (see Table 1 7  for coefficient estimates). 
Significant variability was observed in initial status, however, BAI growth rate was not 
found to significantly differ among clients. The non-significant result of the test of zero 
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covariance between the intercept and slope suggests that the client' s  initial status of 
anxiety symptom severity has no influence on the rate or direction of change in anxiety 
symptom severity over the first five treatment sessions. Therapist level of training (more 
months of training), concomitant psychotropic use, and comorbidity were positively 
associated with baseline levels of anxiety symptom severity, when all covariates were 
entered into the model (Table 1 8). None of the aforementioned covariates predicted rate 
of change at conventional levels of significance. However, having a therapist with more 
months oftraining marginally predicted an accelerated decrease in slope (f3 -0.075, p  = 
.059). The R-square statistic for the latent growth curve parameters suggests that the 
covariates significantly accounted for variation in the intercept (R = 0. 1 96, p = .002) but 
not the slope (R = 0.307, p = .367). 
Table 1 7  
Parameter Estimates and Fit Indices for BAI Growth Models with Covariates 
Model 
Linear spline 
with time score 
residual 
co variances 
fixed to equal 
Mean of 
level 
Coeff. 
(SE) 
8.0 12***  
( 1 .885) 
Variance 
of level 
Coeff. 
(SE) 
63 .362** *  
( 1 1 .933) 
Mean Parameter Covariance: 
of Variance level and 
change of change change 
Coeff. Coeff. Coeff. 
(SE) (SE) (SE) 
- 1 . 573 2.642 -4. 165 
(0.989) (3 .826) (5.994) 
Note. BAI = Beck Anxiety Inventory. Coeff. = Coefficient. SE = Standard Error. df= 
degrees of freedom. * * *  p < .0001 .  * *  p < .00 1 ,  * p < .05, + p < . 1 .  
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Table 1 8  
Covariate Regression Coefficients in Best-Fitting BAI Model 
Covariate Latent Coefficient (SE) p-value 
Factor 
Therapist Level of Training Intercept 0.0 1 9  (0.007) .012  
Medication Status 0.44 (0. 1 5) .005 
Comorbidity Status 0.445 {0. 1 12) <.0001 
Therapist Level of Training Slope -0.038 (0.025) . 1 2  
Medication Status -0.63 (0.47) . 1 9  
Comorbidity Status -0. 1 8  {0.28} .53 
Note. SE = Standard Error. 
Analytic Step 3.2 
Pretreatment Predictors of Trajectories of Early Change. In this section 
predictors explaining heterogeneity in initial status (intercept) and growth rate (slope) are 
reported (see Table 1 1  ). The univariate predictor analyses (including the three covariates: 
therapist level of training, medication status, comorbid status) identified the following 
variables as predictors ofBAI initial status: therapist level of training, medication status, 
comorbidity status, depressive symptom severity, and global functioning. Specifically, 
therapists with more months of training, concomitant psychotropic usage, comorbidity, 
greater depressive symptom severity, and poorer functioning were predictive of greater 
anxiety symptom severity at intake. 
Three variables were identified as predictors of growth rate: therapist level of 
training, depressive symptom severity, and a contemplative orientation to change. That is, 
clients paired with therapists with more months of training demonstrated a significant 
accelerated decline in anxiety symptoms over the first five treatment sessions. And, 
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greater initial depressive symptom severity and higher pretreatment contemplation scores 
predicted a steeper decline in anxiety symptomatology. 
Next, a multivariate predictor analysis that included all pretreatment factors was 
run (see Table 1 2). This model identified the following as significantly related to initial 
status: therapist level of training, depressive symptom severity, and global functioning. 
Specifically, greater therapist level of training, greater depressive symptom severity, and 
lower functioning were associated with greater anxiety symptom severity at intake. In 
addition, clients matched to therapists with more months of training and those with 
greater depressive symptom severity, a contemplative orientation to change, and lower 
maintenance SOC subscale scores predicted an accelerated decline in anxiety 
symptomatology in the multivariate analyses. 
In sum, fewer predictors of initial status of anxiety symptom severity were 
identified. When all other variables were accounted for, therapist level of training, 
depressive symptom severity, and global functioning were significantly related to initial 
anxiety symptom severity. Therapist level of training, depressive symptom severity, a 
contemplative orientation to change, and lower maintenance subscale scores were found 
to predict rate of change in BAl. The predictors summarized here were included in the 
following outcome analyses. 
Analytic Step 4.2: Aim 4 
Predictors of Outcome: Trajectories ofChange vs Pretreatment Factors. 
Trajectories of early change in severity of anxiety symptoms were further investigated to 
determine the extent to which initial status and growth rate predicted outcome in terms of 
the three measures reviewed above. Previously identified predictors of response (e.g., 
comorbidity, therapist level of training, readiness to change) were also included in the 
growth modeling framework. Outcome was regressed on these potential predictor 
variables concurrently with the latent growth factors to determine which factors 
••mattered most" in terms of predicting heterogeneity in outcome. 
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The first BAI outcome model regressed global functioning and depressive 
symptom severity on the intercept and depressive symptom severity as well as the 
contemplation and maintenance stages of change subscale scores on the slope, as per the 
results of the multivariate predictor analyses. The model controlled for number of 
sessions in addition to the three covariates. In order to examine the incremental utility of 
trajectories of early change and pretreatment variables all factors were simultaneously 
included as predictors of the overall trichotomous responder variable. Specifically, 
responder status was regressed on the intercept and slope in addition to pretreatment 
variables identified in the literature as predictors of response (i.e., age, gender, student 
status, global functioning, hopelessness, precontemplation and contemplation stages of 
change, achievement-oriented DAS, interpersonally-oriented DAS,  comorbidity, 
medication status, and therapist level of training) in the growth modeling framework. 
This model fit the data well, x2 (96) 1 05 . 1 3 ,p  = .25 ; CFI = 0.989; RMSEA = 
.02 1 .  Slope and initial status predicted to responder status such that an accelerated growth 
rate and lower intake anxiety symptom severity predicted higher responder status (e.g., 
Responder). See Table 1 9  for results of the regression analyses. Hopelessness was the 
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only pretreatment variable to predict outcome. Specifically, higher baseline hopelessness 
predicted a lower responder status (e.g., non-responder). 
The second BAI outcome model was identical to the one examined above except 
that the dichotomous responder variable as per the change in BAI scores at termination 
served as the outcome measure. In addition to regressing the responder status on the 
intercept and slope, the following pretreatment factors were tested in the growth 
modeling framework: age, student status, hopelessness, global functioning, achievement-
oriented DAS, interpersonally-oriented DAS, depressive symptom severity, medication 
status, and therapist level of training. 
Table 1 9  
Predictors of Distal Outcomes 
Model Outcome Intercept p-value Slope p-value BHS p-value R 
Variable Coeff Coeff 
{SE) {SE) 
BAI Responder -0.020 .044 -0. 1 99 .007 -0.03 1 .01 2  39 .4% 
Status (0.0 10) (0.074) (0.01 2) 
BAI 0.001 .86 -0.202 .0 1 5  54.0% 
Responder (0.006) (0.083) 
Status 
BAI Total 0.750 <.000 1 1 .673 . 1 16 55 .9% 
Score {0.076) {1 .064} 
Note. Coeff = Coefficient. SE = Standard Error. BAI = Beck Anxiety Inventory. BHS = 
Beck Hopelessness Scale. 
This model fit the data well, x2 (86) = 1 0 1 .52, p . 12; CFI = 0.982; RMSEA = 
.029. The slope predicted to responder status such that an accelerated growth rate 
predicted higher responder status (e.g., Responder) whereas the intercept was not 
identified as a significant predictor. Not a single pretreatment variable predicted response 
over and above latent growth factors. 
57 
The third and final BAI outcome model included the BAI total scores at 
termination as the outcome measure. In addition to regressing the termination scores on 
the intercept and slope, the following pretreatment variables were tested in the growth 
modeling framework: age, gender, student status, hopelessness, global functioning, DAS, 
achievement-oriented DAS, interpersonally-oriented DAS, comorbidity, medication 
status, and therapist level of training. 
This model fit the data well, x2 ( 109) = 120.65, p = .2 1 ;  CFI 0.988; RMSEA = 
.022. The slope did not predict to responder status whereas greater intake anxiety 
symptom severity predicted higher BAI scores at termination. Not a single pretreatment 
variable predicted response over and above latent growth factors. 
In sum, the intercept and slope of the best-fit linear spline growth curve modeling 
the BAI scores at intake and over the first five treatment sessions predicted outcome on 
two measures under consideration. These latent growth factors demonstrated predictive 
validity even when controlling for therapist level of training, comorbidity, and 
medication status as well as number of sessions and a number of other pretreatment 
factors. Hopelessness was the only pretreatment variable to predict outcome when the 
growth factors were simultaneously considered. These results suggest both initial status 
and rate of early change in anxiety symptom severity predict outcome more so than other 
pretreatment variables. 
Analytic Step 5: Aim 5 
Relationship between Depressive and Anxiety Symptoms. Two hypotheses 
regarding the best characterization of the relationship between depression and anxiety 
symptom severity were considered: ( 1 )  a distal pathway through latent growth factors 
(i.e., intercept and slope); (2) a proximal pathway through observed session-by-session 
BDI and BAI scores. Three models were run to test these hypotheses. 
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Preliminary analyses indicated a strong relationship between depressive and 
anxiety symptom severity over the first five treatment sessions. The correlation matrix in 
Table 8 revealed moderate to high, significant bivariate correlations between BDI and 
BAI scores across all time points. 
Test of Hypothesis One: Parallel Models. Because the parallel growth models 
were designed to test the hypothesis that BDI and BAI scores were related through their 
distal latent growth factors, the intercept and slope were entered into a parallel modeling 
structure. Specifically, the intercepts were specified to covary as were the slopes, and the 
BDI slope was regressed on the BAI intercept and vice versa. These additional 
parameters, if significant, would have suggested parallel movement in BDI and BAI time 
scores through distal latent growth factors was indeed characteristic of the sample. 
Even the best-fit model in which the slope for the anxiety growth curve was fixed 
to zero did not demonstrate adequate fit as the Chi-square test was quite significant, 
x(76)2 = 1 1 4.67, p = .0028. This parallel growth model analysis rejected the hypothesis 
that early change in symptom severity was best characterized by relationships through 
distal, latent factors (i.e., intercept and slope). 
Test of Hypothesis Two: Time-varying Covariates. The second set of tests 
examined the hypothesis that a more contemporaneous association characterized the 
relationship between BDI and BAI scores. In order to test this relationship, two additional 
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models were run. First, the best-fit linear spline depression model was subjected to a test 
in which the anxiety scores were included as time-varying covariates (TVC). Second, the 
best-fit linear spline anxiety model was subjected to a test in which the depression scores 
were included as TVC. 
The model in which anxiety symptom scores were introduced as TVC fit less than 
adequately as per the Chi-square test of significance (x(57i 84.52, p .0 1), however, 
adequate fit was demonstrated by both the CFI (.974) and the RMSEA (.047). This model 
suggested that BAI scores at session 1 predicted BDI scores at session 1 ,  and BAI scores 
at session 2 predicted BDI scores at session 2 and so on. Said differently, the hypothesis 
that the relationship between depressive and anxiety symptoms is quite proximal was not 
rej ected, however, because the Chi-square index was not significant one final test was 
run. 
Finally, the reverse model whereby depression symptom scores were introduced 
as the TVC to the overall anxiety linear spline model was run. Though this model still did 
not fit the data adequately as per the Chi-square test of significance (x(58)2 = 79. 1 4, p  = 
.034, adequate fit was demonstrated by both the CFI (.978) and the RMSEA (.04 1 ) .  This 
fit was a significant improvement from the previously reported model as per the Chi­
square difference test (nested x2= 5.38, df= l , p  < .05). This model, in comparison with 
the previous model, suggests the relationship between depressive and anxiety symptom 
severity scores is best characterized by depression symptom severity scores directly 
significantly predicting anxiety symptom severity scores, session-by-session, over time. 
CHAPTER IV 
DISCUSSION 
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This study set out to examine trajectories of depressive symptomatology during 
the first five treatment sessions and the extent to which pretreatment factors relate to the 
depressive trajectories. A second aim was to compare how well depressive symptom 
trajectories versus pretreatment variables predict ultimate therapy outcome. Aims 3 and 4 
were identical to aims 1 and 2 with the exception that anxiety symptoms were the focus 
of investigation. Finally, this study was designed, as a fifth aim, to test two hypotheses 
regarding the relationship between depressive and anxiety symptoms and their change 
over the course ofCBT. 
The discussion of the findings begins with those related to trajectories of change, 
followed by those related to how well pretreatment variables predicted these trajectories 
of change. Next, the results of the tests ofhypotheses related to the relationship between 
depressive and anxiety symptoms will be discussed. Following this section, the results 
related to the comparative predictive utility of both rates of early change and pretreatment 
variables is discussed. Finally, the limitations, methodological and clinical implications, 
and future directions for this line of research are identified and described. 
6 1  
Trajectories of Early Change 
Latent Growth Curve Modeling (LGCM) was employed to characterize the 
trajectories of early change in depressive and anxiety symptom severity from intake 
through the first five treatment sessions of CBT. Results revealed 1 )  significant 
variability in both depressive and anxiety symptoms at intake; 2) a heterogeneous and 
steep rate of change in depressive symptoms accounting for 86% of the total 
improvement in depressive symptomatology; 3) a homogeneous and flatter rate of change 
in anxiety symptoms accounting for 70.2% of the total improvement in anxiety 
symptomatology; and, 4) no relationship between initial severity of depressive or anxiety 
symptoms and rate of change in these symptoms. 
That the LGCM revealed no significant correlation between intercept and slope in 
either the depressive or anxiety symptom profiles suggests that initial severity has no 
influence on the trajectory of early symptom change. Few studies have reported on this 
relationship despite its relevance to understanding the process by which symptoms 
change over the course of therapy. However, Santor and Segal (2001 )  similarly reported 
that pretreatment depressive symptom severity was unrelated to rates of early symptom 
reduction. They highlight the importance of this lack of relationship because it suggests 
that rapid early symptom reduction is equally achievable in clients with anywhere from 
mild to severe pretreatment depressive symptom severity (Santor & Segal, 200 1 ). 
This is not to say that the initial symptom severity scores were not meaningfully 
related to trajectories of change or worthy of further discussion. Rather, the largest drop 
in client depressive and anxiety symptom severity occurred from intake to session one: 
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56% and 43% of total symptom reduction, respectively. Even so, post hoc analyses 
indicated the drop in symptom severity from intake to session one did not predict the 
subsequent rate of symptom change. It is difficult to determine from the current study's 
data whether clients may have exaggerated the severity of their symptoms to ensure they 
would be offered treatment. It seems more likely that these scores accurately reflect 
clients' experience and that the symptom reduction was in response to the validation and 
hope for improvement engendered by the intake and feedback process. It should be noted 
that all clients participated in a feedback session in which the therapist talked about the 
assessment, discussed treatment options and in some cases provided some initial 
psychoeducation and socialization into treatment and how it would proceed. It is not 
surprising that clients would experience relief and hope as a result of these activities. 
Identification of pretreatment variables that do predict rates of early symptom change will 
be important. 
Pretreatment Predictors of Trajectories of Early Change 
Pretreatment variables, in addition to initial symptom severity, were investigated 
to determine the extent to which they were associated with heterogeneity in initial status 
and predicted rates of early symptom change.  Hopelessness, poorer functioning, lower 
anxiety symptom severity, community member status, and concomitant psychotropic 
usage were associated with lower depressive symptom severity at intake whereas only 
poorer functioning, therapist level of training, and greater depressive symptom severity 
was associated with greater anxiety symptom severity at intake. With respect to rates of 
change, student status, a contemplative orientation to change, and concomitant 
psychotropic usage predicted an accelerated decline in depressive symptoms. Different 
pretreatment variables predicted rate of change in anxiety symptoms: therapists with 
more months of training, a contemplative orientation to change, lower maintenance 
subscale scores, and greater depressive symptom severity predicted an accelerated 
decline in anxiety symptoms. 
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Baseline correlates of pretreatment depressive and anxiety symptom severity have 
been frequently reported in the literature. Indeed, the significant relations observed 
between pretreatment variables and initial status in the present study, such as 
hopelessness and depressive symptom severity, replicate much of what is already known. 
However, there are some unique features of the current sample that were also 
significantly related to initial symptom severity worth mentioning. For instance, the 
sample contained a mix of both students and community members, two subpopulations 
presenting for therapy. Community member status was associated with greater depressive 
symptom severity at intake and decelerated rates of early depressive symptom change. 
Perhaps students with less severe depression presented more frequently because treatment 
was free whereas community members were required to pay. And, it may be that student 
status is serving as a proxy for studiousness that manifested as homework 
compliance/completion--a key ingredient to achieving successful response to CBT (e.g., 
Bryant, Simons, & Thase, 1 999; McEvoy & Nathan, 2005; Persons, Bums, & Perloff, 
1 988). However, the explanations behind these significant relations lack supportive data 
particularly with no comparison points, to our knowledge, available in the literature. 
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Another unique feature of our sample is that therapy occurred in a training clinic 
where therapists demonstrated significant variability in months of training (range: 1 to 53 
months). This range is perhaps more meaningful than a range of 5-10 years, for example, 
given the differing degree of exposure to clients and CBT from even 1 to 6 months. 
Indeed, therapist level of training was associated with initial anxiety symptom severity 
and rate of early anxiety symptom change. That therapist level of training was correlated 
with initial status may reflect the nature of case assignment in the clinic. Therapists with 
fewer months of training were typically assigned less severe clients and vice versa. That 
therapist level of training significantly predicted an accelerated rate of early anxiety 
symptom change suggests that client anxiety symptoms were more effectively and 
efficiently reduced through work with a therapist who had more months of training. 
Similarly, Driscoll, Cukrowicz, Reitzel, Hernandez, Petty, and Joiner (2003) examined 
therapist level of training also in a training clinic and found that total number of client 
contact hours was significantly related to outcome. It seems our results replicate those of 
a growing body of literature that suggests therapist level of training is significantly 
related to good outcomes (DeRubeis et al., 2005 ; Grey, Salkovskis, Quigley, Clark, & 
Ehlers, 2008; Lutz, Leon, Martinovich, Lyons, & Stiles, 2007; Stein & Lambert, 1 995; 
Weertman & Arntz, 2007), but extend the otherwise limited research by identifYing its 
relation to rapid response. 
There is also a dearth of research examining the role of readiness to change on 
treatment outcome, much less on its relation to early symptom change. Recently, 
however, readiness to change has been identified as a predictor and mediator of treatment 
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for adolescent depression. Specifically, Lewis, Simons, Silva, et al (2009) found that 
higher scores on the action subscale were predictive of successful response to CBT, 
medication, and their combination and that increases in action scores were facilitated in 
CBT conditions which mediated outcome. In the present study, higher contemplation 
subscale scores predicted an accelerated rate of change in both depressive and anxiety 
symptomatology. This finding is in accord with Lichtenberg and Hummel 's (2000) work 
with a similarly depressed and anxious adult sample, the difference being that they found 
higher pretreatment contemplation subscale scores predicted ultimate outcome, rather 
than rate of early change. Until more studies examine the predictive utility of the SOCS, 
it is difficult to say if the identification of contemplation scores, as opposed to action 
scores, as a predictor reflects developmental differences in the way readiness to change 
influences treatment response. Even so, what is consistent about these findings across 
developmental stages is that if clients are at least thinking about changing their symptom­
related behaviors they are more likely to achieve successful outcomes. 
A more widely studied phenomenon is that of medication's effect on rate of 
depressive symptom improvement. Indeed, one of the desirable features of 
antidepressants is that they are fast acting, typically more so than psychotherapies (e.g., 
Hollon, Jarrett, Nierenberg, Thase, Trivedi, & Rush, 2005; Keller et aL, 2000). The data 
presented here are no exception--concomitant psychotropic usage was significantly 
associated with an accelerated rate of change. Interestingly, although initial symptom 
severity and rate of change significantly differed according to medication status, in tenns 
of depressive symptom severity, no termination differences were observed. These 
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findings support the growing literature that medication bolsters the effect of CBT for 
depression, or vice versa, but that combination treatment does not offer the same benefits 
in terms of anxiety (Otto, Smits, & Reese, 2005). There is some literature that suggests 
combining CBT with medication in the treatment for anxiety disorders reduces the 
overall clinical effectiveness (e.g., Barlow et al., 2000). That anti-anxiety medications, as 
their name would suggest, minimize the client's experience of physiological symptoms 
during an exposure is problematic from a CBT perspective. In support ofthis notion, 
despite the significant improvement in depressive symptoms in our sample accelerated by 
medication status, clients concurrently on medication demonstrated significantly higher 
rates of anxiety symptoms at termination. 
One final predictor worth discussing is that of initial depressive symptom 
severity. Specifically, greater depressive symptom severity at intake predicted an 
accelerated rate of early anxiety symptom change. Though the direction of this 
relationship may seem counter to one's  expectations, these findings potentially fit with a 
new line of comorbidity research. Through an innovative experimental design, Craske 
and colleagues found that individuals with comorbid disorders treated specifically and 
solely for panic responded significantly better than individuals with comorbidities treated 
for panic and their most severe comorbid disorder. Their interpretation, simply put, is that 
less is more. That is, it seems focusing on a range of client symptoms was less effective 
than delivering treatment focused on a single symptom set (Craske, Farchione, Allen, 
Barrios, Stoyanova, & Rose, 2007; Tsao, Mystkowski, Zucker, & Craske, 2005). 
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Although there was no experimental manipulation in the present study or 
adherence data to confirm the following, the findings reported here were obtained in a 
therapeutic setting whereby CBT was typically delivered consistent with Craske's  "less is 
more" approach. As such, greater initial depressive symptom severity would have 
suggested that the therapist target depressive symptoms. If the above-summarized 
research holds, it follows that change in depressive symptom severity would then predict 
change in anxiety symptom severity. A direct test of this explanation would require 
simultaneous modeling of depressive and anxiety symptoms. Surprisingly few studies 
have examined the patterns of change in depressive and anxiety symptoms 
simultaneously. Persons, Roberts, and Zalecki (2003) used mixed modeling to examine 
the extent to which depressive symptoms predicted anxiety symptoms and vice versa in a 
highly comorbid sample. As expected, they observed a strong relationship between 
symptoms though they reported no differential effect indicating one more strongly 
predicted the other. It is difficult to say whether Persons and colleagues targeted 
interventions on a single symptom set or if both depression and anxiety were treated 
simultaneously. 
Relationship between Depressive and Anxiety Symptoms 
In an effort to replicate and extend the work of Persons and colleagues (2003), we 
tested two hypotheses regarding the relationship between depressive and anxiety 
symptoms: ( 1 )  depressive and anxiety symptoms are more distally related through latent 
constructs; (2) depressive and anxiety symptoms are more proximally related as 
evidenced by significant time-varying covariate relationships between symptom scores 
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within each session. The first hypothesis was rejected: the parallel growth modeling did 
not fit the data well, nor did the expected regression equations and covariance 
relationships reach significance. However, the second hypothesis, which included 
symptom scores as time-varying covariates fit the data well. Different from Persons and 
colleagues, our method of analysis allowed us to conclude, based on comparisons of 
model fitness, that the relationship between depressive and anxiety symptoms was best 
characterized as contemporaneous in nature such that depressive symptoms most strongly 
predicted anxiety symptoms. These results support our interpretation presented above that 
targeting depressive symptoms leads to change in anxiety symptoms. Nevertheless, given 
the lack of data regarding specific interventions delivered and/or mechanisms of change, 
these results are speculative and descriptive at best. 
Predictors of Outcome: Trajectories ofChange vs Pretreatment Factors 
Thus far this discussion has focused on rates of early symptom change and their 
predictors. However, these findings matter not ifthere is no relation to outcome. Indeed, 
the overarching goal of this dissertation was to determine which "mattered most" in 
predicting treatment outcome: trajectories of early change or pretreatment factors. The 
current study is the first to simultaneously compare these two approaches to the 
prediction of acute treatment outcome. Results suggest that the rate of change in 
depressive symptoms over the first five treatment sessions significantly and consistently 
predicted outcome over and above the majority of pretreatment variables, except for 
precontemplation stages of change scores, and initial severity of depression and anxiety 
symptoms. Similarly, rate of change in anxiety symptoms significantly predicted outcome 
on two of the three measures over and above the majority of pretreatment variables, 
except for hopelessness and initial symptom severity of anxiety. 
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With respect to depressive symptomatology, the rate of early change in BDI 
scores was the only predictor that emerged across all three measures of outcome 
explaining an average of 5 1 %  of the variability in response at termination (see Table 1 6  
for R2 estimates). The consistency with which rates of early depressive symptom change 
predicted outcome suggests it is indeed a robust predictor as it emerged even when 
controlling for number of sessions and 1 6  other pretreatment factors previously identified 
as predictors of outcome. Two other studies have examined the incremental utility of 
rates of early symptom change with respect to symptom return at follow-up (Gilboa­
Schechtman & Shahar, 2006; Santor & Segal, 2001 ). Similar to the results reported here, 
they found that rate of early symptom change (by the 4th or l Oth week of treatment) 
predicted outcome at 3-, 12-, and 1 8-months since termination over and above 
pretreatment depressive symptom severity, symptom reduction in other phases of 
treatment, and remoralizer status.  Our study adds to this developing literature specifically 
that early rate of depressive symptom change can predict to acute outcomes, not simply 
to follow-up, and that its predictive utility prevails over numerous previously identified 
pretreatment predictors of outcome. 
With respect to anxiety symptomatology, the rate of early change in BAI scores 
was the only predictor that emerged across two of the three measures of outcome 
explaining an average of 50% ofthe variability in response at termination (see Table 1 9  
for R2 estimates). Although this finding did not reach conventional levels of statistical 
significance (p = . 1 1  ), the rate of early change in BAI scores predicted BAI scores at 
termination (the third outcome measure) in the expected direction. So despite the 
significantly slower rate of change in anxiety symptoms and its demonstrated 
homogeneity in the current sample, its predictive utility mirrors that of rate of early 
change in depressive symptoms. These results, however, are quite preliminary and 
warrant replication. 
70 
Perhaps surprisingly, only four pretreatment variables (i.e., precontemplation 
subscale scores, hopelessness, depressive and anxiety symptom severity) predicted 
treatment outcome when rates of early change were simultaneously considered. 
Specifically, higher precontemplation subscale scores predicted responder status as per 
change in BDI scores at termination. There is no literature to support the direction of this 
fmding as high pretreatment precontemplation scores are typically associated with 
treatment dropout. However, it may be that the therapists in our clinic "flagged" these 
clients with high scores on the precontemplation subscale at intake. There is a strong 
emphasis in the training clinic to use all assessment materials to inform subsequent 
treatment decisions. If indeed therapists were keenly aware of this pretreatment 
prognostic indicator and tailored treatment accordingly by supplementing CBT with 
Motivational Interviewing, it may have been that these clients who were initially "at risk" 
for dropping out received a supplemental intervention that improved their rate of 
response. The only way to test this interpretation with the dataset would be to examine 
whether precontemplation scores were reduced and contemplation or action subscale 
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scores were increased over the course of therapy. This meditational analysis is indeed an 
important future direction for this kind of work. 
Higher pretreatment hopelessness scores predicted poorer response on the 
trichotomous outcome variable: Non-responder, Partial Responder, or Responder. 
Although it might seem strange that hopelessness emerged as a predictor of response with 
respect to anxiety symptom modeling, and not the depressive symptom modeling, this 
result suggests that in individuals with comorbid disorders (as in our sample) both rate of 
early anxiety symptom change and pretreatment hopelessness significantly predicted 
outcome. That is, hopelessness did not predict outcome with regard to depressive 
symptom modeling perhaps because it was redundant with depressive symptom severity 
whereas hopelessness uniquely accounted for variance when anxiety symptom severity 
was the focus. 
Initial depressive and anxiety symptom severity were the only other pretreatment 
predictors of response that emerged when rates of early symptom change were 
simultaneously considered. In a review, Hamilton and Dobson (2002) suggest results 
regarding the predictive utility of initial symptom severity in CBT are equivocal. Even 
within one study we are unable to report, consistently, whether initial symptom severity 
"matters" in terms of outcome. One thing is consistent about these predictors-they only 
emerged when total symptom scores (i.e., BDI or BAI) were the outcome variable under 
consideration and not when responder status based on clinically significant change 
indices was the focus. This distinction seems important because it suggests that while 
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significant differences in total symptom score were observed, initial status had no bearing 
on clinically significant symptom change over treatment. 
Predictors of Outcome: Post Hoc Comparisons 
This study was successful in comparing the incremental utility of trajectories of 
early change and pretreatment variables to the prediction of outcome by simultaneously 
regressing outcomes on all factors of interest. The typical approach to the identification 
of outcome predictors includes either consideration of rates of early response or 
pretreatment variables. It was thus decided a posteriori to explore the extent to which 
separate examination of these factors would have yielded different results. Indeed, post 
hoc analyses revealed different predictors of outcome when examining trajectories of 
change and pretreatment variables separately for both depressive and anxiety 
symptomatology. 
With respect to depressive symptomatology, when the intercept and slope 
regression equations were dropped from the outcome analyses, hopelessness, global 
functioning, precontemplation, contemplation, and maintenance subscale scores predicted 
response. Conversely, when outcome was regressed only on the intercept and slope of the 
depressive symptom growth model both latent growth factors significantly predicted 
outcome across all measures. 
With respect to anxiety symptomatology, when the intercept and slope regression 
equations were dropped from the outcome analyses, hopelessness, student status, 
precontemplation, contemplation, and maintenance stages of change scores predicted 
response. Conversely, when outcome was regressed only on intercept and slope of the 
anxiety symptom growth model both latent growth factors significantly predicted 
outcome across all measures. 
Methodological Implications 
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This is the first study, to our knowledge, to simultaneously compare trajectories of 
early symptom change and pretreatment variables to detennine which matters most in the 
prediction of outcome. These results together with Gilboa-Schechtman and Shahar's 
(2006) and Santor and Segal's (200 1) work highlight the importance of simultaneously 
comparing rates of early symptom change and pretreatment variables. There is now 
evidence that rates of early symptom change predict acute outcome in addition to 
outcomes at 3-, 12- and 18-month follow-up over and above pretreatment variables. 
The addition of the post hoc analyses presented here are particularly illuminative. 
Both the intercept and slope of the depressive and anxiety growth models predicted 
outcome when examined separately. And, numerous pretreatment variables predicted 
outcome when examined separately. Therefore, the significance of the predictors was 
contingent solely upon the approach to analyses reaffirming the importance of 
simultaneously testing the predictive or incremental utility of rates of early symptom 
change and pretreatment variables. Researchers are thus encouraged to simultaneously 
test both sets of factors when investigating predictors of outcome in order to best utilize 
all available information. Investigating pretreatment factors separate from growth rates, 
or vice versa, may be misleading. 
An important piece of our recommendation hinges on one's ability to collect 
session-by-session data. Investigators of the current study had the fortunate opportunity 
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to work closely with a computer science technician to merge paper outcome measures 
with a confidential paperless system. This system facilitated our ability to collect a very 
rich dataset for the purposes of conducting research. In addition, this system was 
designed to be user-friendly to meet the needs of both clients and therapists. This system 
was a success in terms ofboth research accessibility and clinical utility and is highly 
recommended. 
Clinical Implications 
Predictors have long been the focus of treatment outcome research in an effort to 
identify prognostic indicators to aid in therapist treatment planning. However, few 
predictors of CBT have been consistently identified (Hamilton & Dobson, 2002) making 
it difficult for the therapist to make sense of the large body of literature that exists. 
Conversely, the predictive utility of rapid early response to treatment appears to be a 
robust finding in the literature. The present study provides additional information 
suggesting that rates of early symptom change may be our best indicator of successful 
outcome. Therefore, in terms of clinical implications, it seems important that therapists 
systematically monitor symptom severity particularly over the first five to ten treatment 
sesswns. 
This is not to say that clients who are not demonstrating rapid response should 
then be terminated. Rather, predictors of rapid rates of response might serve as a guide 
for treatment planning. For instance, higher scores on the contemplation SOC subscale 
predicted an accelerated decline in both depressive and anxiety symptom severity. Logic 
follows that in order to facilitate rapid early symptom change, interventions such as MI 
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might be important for the therapist to employ early in treatment. As this line of research 
grows, identification of additional predictors of early symptom change will be important. 
In sum, this research may help therapists identify individuals who are at risk of not 
responding to treatment earlier on so as to tailor treatment accordingly. 
The majority of the discussion, thus far, has been devoted to highlighting, and 
making sense of, significant predictors of rates of early symptom change and outcome. 
Switching gears to focus on a non-significant predictor--comorbidity--seems equally 
important given the role it has already played in this discussion. That comorbidity did not 
predict trajectories of early symptom change or outcome is indeed quite important when 
thinking about the clinical implications of this work. Community therapists all too readily 
disregard ESTs because the efficacy tradition ruled out clients with comorbidities (Addis, 
Wade, & Hatgis, 1 999; Mahrer, 2005). However, the results from the present study 
replicate a burgeoning literature that suggests comorbidity does not predict outcome 
(Joormann, Kosfelder, & Schulte, 2005; McLean, Woody, Taylor, & Koch, 1 998; 
Persons, Roberts, & Zalecki, 2003). In the current study, comorbidity did not predict rate 
of early symptom change or outcome or number of sessions required to reach natural 
termination. Rather, therapist level oftraining was identified as a predictor of rapid early 
symptom change, at least with regard to anxiety symptoms, demonstrating predictive 
utility over and above that of comorbidity. Indeed, research suggests that the effect of 
comorbidity may be minimal whereas the competence of the clinician may instead predict 
outcome. Specifically, although Kuyken and Tsivrikos (2009) replicated the finding that 
76 
CBT for depression outcomes were compromised for clients with comorbidity, they 
found that therapist competence predicted improved outcomes regardless of comorbidity. 
Limitations 
There are several noteworthy limitations to the present study. First, although 
therapist level of training was identified as a predictor of initial status and rate of change 
in anxiety symptomatology, it is unclear what therapist level of training is actually 
measuring other than simply months since entering practicum. A potentially more 
informative construct to examine would be actual therapist competence-a likely 
candidate for explaining the relation between therapist level of training and rapid 
recovery observed in this study. However, months or years of training may have little to 
do with the competence of the therapist (Waltz, Addis, Koerner, & Jacobson, 1 993). 
Relatedly, our study lacks the data to elaborate on treatment fidelity. Although it was 
described above that therapists delivered CBT and its third wave variants through the lens 
of a cognitive case conceptualization, we do not have data to support this claim. Fidelity 
measurement and competency ratings are thus both a limitation and a future direction of 
ours. 
Second, although the present study was derived from a rich dataset with 1 6  
potential pretreatment factors included in the predictor analyses, some important 
variables were omitted from the study. For instance, Hamilton and Dobson (2002) 
identified the chronicity of depression as a fairly robust predictor of response that was not 
included in our dataset. Indeed, we hypothesized that chronicity may be the variable most 
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strongly related to therapist level of training as it was thought to heavily influence client­
therapist assignment; however, we were unable to test this hypothesis. 
Third, given the range of anxiety disorders represented in the current sample and 
the limited focus of the BAI on somatic manifestation of anxiety symptoms, a different or 
an additional measure of anxiety might have yielded greater variability in rate of 
symptom change. For instance, the Symptom Checklist has been employed by others 
studying rate of change (e.g., Kopta, Howard, Lowry, & Beutler, 1 994). This measure 
appears to tap into a broader range of anxiety symptoms including, for example, general 
anxiety, phobias, and obsessive-compulsive symptoms. 
Fourth, for a number of reasons, the generalizability of this study might be 
somewhat limited. Specifically, clients with acute suicidality, psychosis, and concurrent 
substance dependence/abuse were referred out for more appropriate services. Similarly, 
the average symptom severity of the sample was mild-moderate suggesting few cases of 
severe nonpsychotic depression were represented in this sample. Further, the 
homogenous nature of the clients in terms of ethnicity and culture limits the 
generalizability. Therefore, the findings presented here cannot be assumed to reflect 
trajectories of change and predictors of outcome in clients with more severe and 
persistent mental illness or clients of more diverse cultures. Rather, it might be 
appropriate to conclude that the clients in the current study represented a subset of those 
seeking outpatient psychotherapeutic services. 
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Future Directions 
There are numerous potential avenues for future research. First, although the 
present study collected data on session-by-session rate of change in symptom severity, it 
would be important to collect additional data on potential mechanisms of change. 
Because of the robust nature of the predictive utility of the rapid rate of response, 
researchers have engaged in a debate over whether it is general therapy factors (e.g., 
working alliance; Ilardi & Craighead, 1 999) or therapy specific factors (e.g., change in 
cognitive distortions; Tang & DeRubeis, 1 999), however, the field has yet to resolve what 
exactly is responsible for this rapid change. 
Second, separate subgroup analyses would allow for a more nuanced test of the 
effect of comorbidity. That is, rather than simply including comorbidity as a pretreatment 
factor, comorbidity groups could be analyzed separately and compared to determine the 
extent to which similarities and differences exist. For instance, in the current analysis the 
clients with a single Axis I diagnosis were all included in the same group. It may be that 
single anxiety disordered clients responded differently than did single depressive 
disordered clients. These differences might have implications for treatment planning. 
Third, it may be that the average, overall, rate of growth identified in the current 
sample actually consisted ofunobserved subgroups of individuals that could be identified 
through growth mixture modeling (GMM). GMM relaxes the assumption that individuals 
in a sample come from the same population. Rather, it assumes that there are 
subpopulations of individuals that manifest in different patterns of response. GMM then 
enables one to characterize group membership through the exploration of pretreatment 
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factors and time-varying co variates. And, within-group differences in terms of rate of 
change can be investigated in addition to the extent to which group differences predict 
response. The capabilities of GMM have only recently been applied to treatment outcome 
research and have yielded very different outcomes than more standard approaches have 
allowed. 
Finally, given the recent push to disseminate CBT and the robust predictive utility 
of rapid early response it is increasingly important to identify ways in which to maximize 
the rate of early change. Perhaps Roz Shafran's hypothesis is accurate, that holding 
sessions twice a week for the first three weeks would achieve this goal. However, an 
empirical test comparing session dose and early rates of change is in order prior to 
disseminating this approach to session dose. 
Conclusion 
In conclusion, the present sought to answer the question "Which clients responded 
to CBT?" through the merging of two different methodological approaches. Results 
suggest that the rates of depressive and anxiety symptom change over the first five 
treatment sessions predicted outcome over and above the majority of pretreatment 
variables. Pretreatment predictors of rate of early symptom change, such as a 
contemplative orientation to change and therapist level of training, were identified which 
may suggest that therapists should target these factors to potentially maximize rapid early 
symptom change, and in tum outcome. 
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